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Although HIV-1 can be adequately controlled by combination antiretroviral 
therapy (cART), it is still an incurable disease due in part to the latent reservoir that 
persists in resting CD4+ T cells (rCD4s). Latently infected rCD4s do not actively express 
HIV-1, allowing them to evade immune surveillance, but their ability to reinitiate viral 
expression maintains this barrier to a cure. Shock-and-kill, a prominent strategy for HIV-
1 eradication, requires the reactivation of latent HIV-1 gene expression.  
Global T cell activation is a well-characterized means of inducing HIV-1 
transcription, but is considered too toxic for clinical applications. Here, we explore a 
strategy involving a combination of immune activation and the immunosuppressive 
mTOR inhibitor rapamycin. We show that rapamycin downregulates markers of toxicity, 
including pro-inflammatory cytokine release and cellular proliferation, induced by potent 
T cell activating agents. Using an ex vivo assay for HIV-1 mRNA in rCD4s from infected 
individuals on antiretroviral therapy, we demonstrate that despite this immunomodulatory 
effect, rapamycin does not affect HIV-1 gene expression induced by T cell activation. In 
contrast the immunosuppressant cyclosporin, a calcineurin inhibitor, robustly inhibits 
HIV-1 reactivation. Importantly, cytotoxic T lymphocyte (CTL) recognition and killing of 
infected cells is also not impaired by rapamycin treatment.  
These findings are also being extended to HIV-positive individuals requiring solid 
organ transplant, which acts an in vivo immune activating stimulus without the need for 
additional intervention. A previous study has shown that a group of these patients who 
received rapamycin for immunosuppressive maintenance had lower levels of HIV-1 DNA 
in peripheral blood cells when compared with patients receiving a calcineurin inhibitor 
such as cyclosporin. This previous finding is in support of our findings, and suggests that 
rapamycin may allow for shock-and-kill in vivo. Here we compare pre- and post- 
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transplant reservoir size using a novel assay, the quantitative viral induction assay 
(QVIA), and discuss the surprising result of an increase in the size of the HIV-1 latent 
reservoir post-transplant. 
Alternatively, compounds that may not elicit T cell activation phenotypes, and are 
not necessarily thought to act via any of the same pathways as T cell activation, may 
effectively stimulate HIV-1 transcription. Several latency reversing agents (LRAs) have 
activity in primary rCD4s isolated from patients on cART, including PKC agonists, HDAC 
inhibitors (HDACi), and bromodomain and extra-terminal (BET) bromodomain inhibitors. 
Of particular interest are HDACi, as there are several drugs in this class approved for 
clinical use. Although the activity of HDACi on HIV-1 expression is well documented; 
they act synergistically with other LRAs in primary cells and have high activity alone in 
several cell models for latency; these drugs have a broad scope of activities and their 
mechanism of action in this context is controversial. If a mechanism can be identified, a 
more targeted approach to reactivate latent HIV-1 may be developed. We therefore used 
a combination of gene expression and transcription factor array studies in the context of 
both primary and model cells to further understand how HDACi may be acting upon HIV-
1 transcription. Using specific small molecule inhibitors we have identified a potential 
role for p21 in HDACi activity on latent HIV-1. 
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Introduction 
An estimated 35 million people worldwide are infected with HIV, yet a widely 
applicable cure strategy remains elusive. Recent case reports have suggested that cure 
of HIV infection is possible, renewing excitement for cure research efforts. Here, we 
describe those cases and discuss their relevance to the global HIV epidemic. We also 
review ongoing cure strategies that are transitioning from the lab to the clinic, and the 
assays and clinical assessments that can be used to evaluate cure interventions. 
Infection with human immunodeficiency virus type 1 (HIV-1) is a continuing global 
health concern, with ~1.5 million AIDS-related deaths worldwide in 2013. Current 
combination antiretroviral therapy (cART) reduces viremia to undetectable levels, 
preventing further loss of CD4+ T cells and progression to AIDS. cART allows HIV-
infected individuals to have near-normal life expectancy. (1) However, cART is not 
curative, and infected individuals must remain on therapy for life to maintain health.  
Here we review the need for a cure, the barriers to achieving this goal, exciting recent 
cases in which a cure has been achieved or nearly achieved, and strategies to make 
HIV-1 infection curable.  
As therapy for HIV-1 infection has improved, the need for curative interventions, 
particularly those that pose risk to the patient, has been questioned.  The benefits of a 
cure are best understood in the context of the global epidemic.  According to the Centers 
for Disease Control and Prevention, only 36% of infected individuals worldwide are 
receiving cART.  This is partly a financial issue, with lifetime cART estimated to cost 
$379,668 in 2010 (http://www.cdc.gov/hiv/prevention/ongoing/costeffectiveness/). The 
majority of HIV-infected individuals worldwide live in low-income countries with more 
limited access to healthcare.   Moreover, the number of people living with HIV-1 globally 
continues to increase, threatening to elevate the cost of HIV-1 healthcare to 
unsustainable levels. Although prevention strategies have allowed the number of new 
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HIV-1 infections per year in the United States to remain stable, the prevalence of HIV-1 
is increasing because infected individuals live longer on cART.  In addition, results from 
the Strategic Timing of Antiretroviral Treatment (START) trial have suggested that 
beginning cART as early as possible is best for long-term patient outcomes. (2) These 
findings will likely influence patient care, broadening the indication for these drugs to all 
HIV-infected individuals, a prospect that will clearly be unsustainable unless a cure is 
found. 
At the level of the individual patient, there are also reasons why a cure, even one 
involving some risks, would be preferable to lifetime cART.  Adverse long-term effects 
such as lipodystrophy are associated with some antiretroviral drugs.  Drug toxicity can 
decrease adherence. (3) If a patient is poorly adherent or discontinues therapy without 
careful medical supervision, drug resistance can develop.  Resistance makes it more 
difficult to successfully reinitiate treatment later. (4) These problems contribute to the fact 
that only 75% infected individuals on treatment in the United States are able to maintain 
suppression of viral replication. 
For patients able to adhere to cART, CD4+ T cell counts stabilize and increase, 
but the immune system never fully recovers. Even patients who have been on 
suppressive cART for years suffer from increased immune activation and inflammation, 
(5) which can lead to additional health problems including cardiovascular disease.  It is 
not clear whether these abnormalities result from legacy effects of the period of 
unchecked viral replication before initiation of cART or from a low level of ongoing 
release of virus from stable reservoirs.  Cure strategies would impact the latter but not 
the former. 
Those infected with HIV-1 would also benefit from a cure for non-medical 
reasons. Along with the high cost of cART, there is the social stigma of being HIV+, as 
HIV-1 infection has historically been associated with drug use and high-risk sexual 
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activity. Therefore, although cART has greatly improved the lives of infected individuals, 
there are significant problems with life-long treatment. Clearly, a cure strategy would 
both benefit infected individuals and reduce the burden to the global health economy. 
Due to a fundamental feature of HIV-1 biology, the infection has proven difficult 
to cure. HIV-1 stably integrates its genome into the DNA of the host cells it infects, 
predominantly CD4+ T lymphocytes. A small number of these infected cells enter a state 
of latent infection and persist indefinitely.  Cells containing a latent HIV-1 genome can 
later resume active virus production.  A single integrated provirus can produce a 
sufficient number of virions to perpetuate infection, and when therapy is discontinued, 
viremia quickly rebounds. (6) Thus, the persistence of latently infected cells is a major 
obstacle to cure. Cure strategies either aim to kill all infected cells or boost immunity to 
control infection. Efforts to produce a cure are accelerating with many different strategies 
currently being studied. 
It is useful at the outset to define critical terms.  Latency is a reversibly non-
productive state of infection. Latent viral infection is characterized by the presence of 
infected cells that do not actively produce virus particles, but retain the ability to do so at 
some point in the future. A viral reservoir is a cell type that harbors replication-competent 
virus for long periods of time. (7) With respect to HIV-1 cure, the only relevant reservoirs 
are those that persist on a time scale of years in patients on optimal cART.  This 
practical definition reflects the fact that cure strategies would only be implemented in 
patients who had suppression of active viral replication on cART for a substantial period 
of time. Another related term is compartment.   This refers to an anatomical site of viral 
replication that has limited exchange of virus with other sites.  
A latent reservoir (LR) for HIV-1 in resting memory CD4+ T cells was 
demonstrated in 1995. (8, 9) The majority of infected cells are activated CD4+ T cells, 
which die quickly due to viral cytopathic effects or host cytolytic mechanisms (t½ = 6 
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hours to 2 days). (10, 11) On rare occasions recently activated cells become infected 
during the transition from activated state to a resting memory state, which is non-
permissive for viral gene expression. This allows long-term persistence of stably 
integrated proviruses in long lived memory T cells. (12) Early studies using a virus 
culture assay to quantify the frequency of latently infected cells demonstrated that this 
reservoir is extremely stable. (13) A recent study re-examined the half-life of the LR in 
CD4+ T cells in patients on newer, potentially more effective cART regimens. The 
authors estimated a mean reservoir half-life of 3.6 years, (14) the same as an original 
study completed 12 years previously, indicating that newer antiretroviral drugs do not 
increase the decay rate of the LR. This suggests that the stability of the LR is not due to 
incomplete suppression of viral replication. The finding that cART intensification does not 
cause additional reductions in the trace level of viremia that can be detected in treated 
patients using sensitive assays also supports this conclusion.(15, 16) 
There are multiple definitions of HIV-1 cure, each being pursued with multiple 
strategies (Table 1). A sterilizing cure is defined as complete eradication of infectious 
forms of the virus from the body; that is, replication-competent provirus is no longer 
present. Another possibility is ART-free remission, a scenario in which the HIV-1 
reservoir is not eliminated but is reduced enough to greatly decrease the chances of viral 
rebound.  Modeling of infection dynamics has predicted that a 3- to 4-log decrease in the 
size of the LR is necessary to achieve ART-free remission of > 1 year. (17) A functional 
cure is thought to be a more attainable goal, as it does not require that the HIV-1 
reservoir be reduced or eliminated.  Instead, a functional cure allows for discontinuation 
of cART without rebound because the immune system is modified in some way so that it 
is able to control viral replication without therapy. (18, 19)  
There is one example of a sterilizing cure. The ‘Berlin patient’ received an 
allogeneic hematopoietic stem cell transplant (HSCT) to treat acute myeloid leukemia. 
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This case was exceptional because an HLA-matched donor was found who was 
homozygous for the CCR5 delta32 mutation, which causes a deletion in the CCR5 
coreceptor needed for HIV-1 entry. Hence, donor cells were resistant to infection. (20) 
Complete chimerism with the delta32/delta32 genotype was achieved 61 days post bone 
marrow transplant, meaning that the patient’s immune system was almost entirely 
replaced by donor cells.  The patient did not experience viral rebound even though cART 
was discontinued at the time of transplant, and HIV-1 DNA could not be detected in 
plasma or rectal mucosa throughout the followup period. (21) The Berlin patient is now 
considered cured, with no detectable HIV-1 present several years later.  It is likely that 
the donor CCR5 delta32/delta32 genotype was crucial to the success of this case. 
Efforts to reproduce this sterilizing cure in patients receiving allogeneic HSCT 
have resulted in ART-free remission, but no additional cures.  Two recently described 
patients, referred to as the ‘Boston patients,’ (22) received transplants for malignancies 
from donors with wild-type alleles at the CCR5 locus. Although donor cells were fully 
susceptible to HIV-1 infection, it was hoped that if the patients maintained cART 
throughout the transplant period, donor cells would not become infected and host cells 
containing HIV-1 proviruses would be completely eliminated by graft versus host 
disease. The idea was to recapitulate the cure seen in the Berlin patient without need for 
an HLA-matched CCR5 delta32/delta32 donor. At 2-4 years after transplantation, neither 
patient had detectable HIV-1 DNA in peripheral blood mononuclear cells (PBMC) by 
PCR, and replication-competent HIV-1 was not recovered from co-cultures. The lack of 
measurable residual host cells and HIV-1 in these individuals suggested complete 
elimination of the LR. However, during closely monitored analytical treatment 
interruptions, the patients experienced viral rebound 3 and 8 months after discontinuing 
cART.(22) 
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It is unfortunately difficult to apply cure strategies used in the above cases to a 
typical patient with HIV-1 infection. Despite the promising results seen with some 
transplant cases, HSCT is only a realistic option for patients with a concurrent condition 
requiring this high risk procedure.  
ART-free remission has also been achieved in a patient known as the 
‘Mississippi baby.’ In this unusual case, a perinatally infected newborn with a high HIV-1 
viral load on the day after delivery was immediately put on cART. Therapy was later 
discontinued against medical advice at 15 months, but surprisingly there was no rapid 
rebound. (23) It was hoped that because the child was started on therapy so early, a 
reservoir of infected memory CD4+ T cells might not have been established. However, 
the child presented with very high plasma HIV-1 at a routine appointment 26 months 
after discontinuing cART. (24) Subsequent cases of early treatment in perinatally 
infected infants have had similar results, with viral rebound after treatment 
interruption.(25) 
Typically, when a patient discontinues cART, there is rapid rebound in viremia 
beginning within 6-15 days and peaking by 21 days post treatment interruption. (6) The 
patients mentioned achieved ART-free remission for longer periods of time, a finding 
with important implications for understanding obstacles to cure. In the Boston patients, 
little to no anti-HIV immunity was present at rebound, consistent with the idea that the 
donor-derived immune systems that developed in these patients had not experienced 
HIV-1 before and therefore had no HIV-specific immunological memory. (22) Therefore, 
the late rebounds after ART interruption were not due to immune control of viral 
replication and can only be explained by persistence of virus in a latent form. Modeling 
of the dynamics of the LR has shown that while a typical pool of latently infected cells 
can cause rebound within two to three weeks, a multi-log decrease in this pool can result 
in a delay from months to years. (17) HIV-1 re-emerges from a latent state when a CD4+ 
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T cell harboring a latent provirus is reactivated by its cognate antigen or another 
activating stimulus. (26) When the total number of latently infected cells is smaller, at 
any given time re-emergence of replicating HIV-1 is statistically less likely.  
A small subset of HIV-infected individuals known as elite controllers (ECs) have 
been viewed as a model for a functional cure, as they are able to maintain very low viral 
loads without therapy and do not progress to AIDS. It was initially thought that EC were 
infected with less virulent strains of HIV-1, but a study examining virus isolated from 
transmission pairs indicates that ECs have this phenotype even when infected with fully 
functional HIV-1 from a chronic progressor.  (27) This and several other studies suggest 
that EC are infected with HIV-1 that is fit and virulent and that these individuals have 
unique immune control over HIV-1. (28, 29) This control may be related to increased 
CD8+ T cell responses(30) and in some patients to the presence of specific HLA class I 
alleles. (31) Although some HLA alleles are over-represented in ECs, these do not seem 
to automatically confer EC status, as patients with progressive disease may also 
possess these alleles. Because the factors contributing to immune control of HIV-1 in EC 
have not been fully characterized, it has proven difficult to develop a therapeutic method 
to recapitulate this state for a functional cure. 
Here, we explore strategies to deplete the LR to achieve sterilizing cure or ART-
free remission. Several strategies toward HIV-1 cure are currently being studied, 
including early cART, which improves long-term health outcomes for patients and may 
induce post-treatment control; vaccination, including preventative or therapeutic 
measures to control infection, and shock-and-kill, which targets the LR that persists long 
term in patients on effective cART. Here, we focus on this latter strategy in an attempt to 
reduce the burden of lifelong HIV-1 infection. 
The shock-and-kill strategy for HIV-1 eradication aims to directly target latent 
HIV-1 in resting memory CD4+ T cells and eradicate all remaining replication-competent 
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HIV-1 from the body in patients on suppressive cART. (32) Since HIV-1 genes are not 
actively expressed in latently infected cells, the first step is to “shock” cells into 
reinitiating HIV-1 gene expression. When cells begin producing viral antigens, they can 
potentially be recognized and targeted by an immune response for the “kill” step. 
 Multiple classes of small molecule latency reversing agents (LRAs) have been 
identified to potentially initiate the “shock” step of this strategy. (33) Histone deacetylase 
inhibitors (HDACis), a class of drugs developed to treat certain cancers, are thought to 
act upon latent HIV-1 by modifying the chromatin state of the LTR promoter, (34) 
although the mechanism remains controversial. (35)  HDACis such as vorinostat and 
romidepsin have been studied thoroughly ex vivo and brought into clinical trials with 
varying levels of success. (36-38) In clinical studies employing shock-and-kill, success in 
perturbing the LR is assessed by looking for transient increases in cell-associated HIV-1 
RNA or viremia to indicate an initiation of HIV-1 gene expression. On a broader scale, 
success in decreasing the size of LR may be determined by measuring inducible virus.   
To date, no LRA has produced a substantial decrease in the size of the LR.  One 
problem is that induction of HIV-1 gene expression is only half of the strategy.  It is also 
important that the infected cells be eliminated after reversal of latency. Shan et al. have 
shown that CD8+ T cells from most patients on cART have only limited ability to kill 
infected cells after reversal of latency (39). They went on to describe a more successful 
approach in which CD8+ T cells were prestimulated with gag peptides to “prime” the 
response. These data suggest that some sort of vaccination may be necessary to 
activate an immune response for the “kill” step. 
A sterilizing cure or prolonged ART-free remission will require a drastic decrease 
in the pool of latently infected CD4+ T cells. Latently infected cells are rare, with an 
average frequency of about 1 cell with replication-competent virus per 106 resting CD4+ 
T cells. (9, 13) For this reason, measuring the LR is difficult.  There is no available 
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clinical assay for the LR.  It is important to have an accurate method to measure a 
change in size of the LR for patients undergoing cure interventions. 
 The gold standard for measuring the LR is the viral outgrowth assay (VOA), in 
which limiting dilutions of resting CD4+ T cells are stimulated with an activating mitogen 
in culture and the amount of infectious virus produced is measured by HIV-1 p24 antigen 
ELISA. (9, 40) This assay has the advantage of detecting only replication-competent 
virus, but has recently been shown to underestimate the size of the LR because some 
replication-competent proviruses are not induced after a single round of T cell activation 
in this assay (41). VOA is also requires a large number of cells and 2-3 weeks of cell 
culture, rendering it more expensive and time-consuming than PCR-based methods.  
 Multiple PCR-based methods have been developed to more easily measure the 
size of the LR. Detection of HIV-1 DNA in unfractionated PBMC or purified resting CD4+ 
T cells can be used to quantify the total number of cells carrying an HIV-1 provirus. (42, 
43) A major caveat of this method that it detects defective proviruses, which do not pose 
a barrier to cure. This discrepancy can lead to an overestimation in the size of the LR by 
as much as 300-fold relative to estimates based on the VOA.(44) 
 PCR detection of induced HIV-1 RNA can also be used to measure the LR. This 
can be done with a T cell activation protocol similar to that used in the VOA, with the 
ultimate readout being RT-PCR detection of HIV-1 RNA instead of ELISA. (45) This 
method is less time-consuming than VOA and more accurate than proviral DNA 
detection, but may pick up some defective proviruses that can be transcribed but cannot 
produce infectious virus. Quantification of HIV-1 RNA transcripts can also be useful in 
identifying effective LRAs for shock-and-kill, as this method can measure HIV-1 
expression changes in patient cells treated ex vivo. (46, 47)  
Recent reports have renewed optimism for curing HIV-1 infection. Unfortunately, 
these cases do not represent the broad cure strategy necessary to impact the global HIV 
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epidemic as they cannot be applied to the vast majority of individuals living with HIV. 
Here, we evaluate broader strategies for HIV-1 cure by shock-and-kill, including the 
previously discarded but potent strategy of T cell activation, and the poorly understood 









HIV-1 persists in a latent reservoir in resting memory CD4+ T cells despite 
combination antiretroviral therapy (cART) (9, 13, 26). Latently infected cells represent a 
major barrier to eradication.  Integrated proviruses in resting CD4+ T cells (rCD4s) are 
minimally transcribed, and thus this reservoir evades immune surveillance. A paradigm 
for HIV-1 cure (37) involves reactivation of proviral expression in latently infected cells to 
allow their elimination by immune mechanisms including CD8+ cytotoxic T lymphocytes 
(CTL) (32). Agents eliciting global T cell activation were used in the original detection of 
the reservoir (9, 26) and effectively reverse latency. However, in clinical settings they 
induce severe adverse reactions by causing systemic release of proinflammatory 
cytokines (48, 49). Although clinical trials using T cell activating agents such as anti-CD3 
and IL-2 have demonstrated transient increases in viremia and changes in HIV-1 
intracellular RNA levels (48), this approach has been abandoned in favor of latency 
reversing agents (LRAs) that induce HIV-1 transcription without cellular activation. While 
promising in cell line models for HIV-1 latency, no single LRA reactivates HIV-1 gene 
expression to levels induced by T cell activation in rCD4s derived from patient samples 
(47). The most effective single agents are PKC agonists, which affect a subset of the 
pathways stimulated by T cell activation (50). Thus, effective latency reversal may 
require some immune activation. This thesis explores the idea that immunomodulatory 
compounds in conjunction with T cell activation may limit toxicity while allowing maximal 
reactivation of latent HIV-1. 
 Adverse reactions elicited by the activation of large numbers of T cells are 
typically attributed to “cytokine storm” (48). A classic example is toxic shock syndrome, 
caused by a staphylococcal superantigen that activates all cells expressing a Vb2 T cell 
receptor (TCR) (about 10% of total T cells) (51). Additionally, agents that induce 
measurable in vitro lymphocyte proliferation have toxicity in vivo. This was dramatically 
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demonstrated by the CD28 superagonist TGN1412, for which other in vitro measures of 
immune toxicity failed to predict the widespread nonspecific immune activation observed 
in vivo (52). 
We asked whether immunosuppressive agents could block the cytokine 
production and T cell proliferation induced by T cell activation without blocking HIV-1 
latency reversal or subsequent killing of infected cells.  Many immunosuppressive 
compounds affect upstream regulators of T cell activation pathways, and thus affect HIV-
1 transcription due to similarities between the HIV-1 long terminal repeat (LTR) and the 
promoters of key genes upregulated by T cell activation including IL-2 (53). IL-2 
signaling is crucial for proper activation of T cells. For instance, the widely used 
immunosuppressant cyclosporin inhibits the calcium-dependent phosphatase 
calcineurin, blocking nuclear translocation of the transcription factor NFAT, which acts 
on both the IL-2 promoter and the HIV-1 LTR (54). Cyclosporin inhibits HIV-1 expression 
induced by a T cell activating agent in a cell line model of latency (55). This makes 
cyclosporin a good control for expected immunosuppressive action on HIV-1 latency 
reversal. 
To avoid inhibition of transcription factors that act upon the HIV-1 promoter, we 
explored immunosuppressants that do not affect signaling immediately downstream of 
TCR engagement. Rapamycin (sirolimus), an inhibitor of the mammalian target of 
rapamycin (mTOR), mediates immune suppression downstream of IL-2 signaling (56). 
mTOR integrates “signal 2” of T cell activation to facilitate metabolic changes needed to 
support cellular growth and proliferation. Rapamycin disrupts formation of mTOR 
complex 1 (mTORC1) which mediates these effects (56) (Figure 1A).  Importantly, 
rapamycin does not affect mTOR complex 2 (mTORC2), which positively regulates PKC 
activation and downstream pathways in T cell activation (56, 57). It has been used in 
HIV-1 infected patients undergoing solid organ and bone marrow transplantation (58). 
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Rapamycin also protects mice from death after superantigen challenge (59). We 
hypothesized that rapamycin treatment would prevent the adverse effects of T cell 
activation without preventing upregulation of HIV-1 transcription.  
 Another consideration is the effect of immunosupressive agents on CTLs. 
Histone deacetylase inhibitors (HDACis), an otherwise promising class of LRAs, have 
been shown to interfere with CTL killing, making this a prominent issue to address (60). 
Cyclosporin may also inhibit CTL function due to a dependence of CTL degranulation on 
calcium influx and downstream signaling (61). In contrast, rapamycin has a positive 
effect on the memory CD8+ T cell response to viral infection (62). We tested whether 
rapamycin interferes with CTL killing of infected cells in the context of HIV-1 shock-and-
kill. 
 
Materials and Methods 
Human Subjects 
Whole blood was obtained from both healthy donor and HIV-1 infected participants.  All 
HIV-1 infected individuals enrolled were on a suppressive antiretroviral therapy regimen 
and maintained undetectable plasma HIV-1 RNA levels (<50 copies per mL) for at least 
6 months prior to enrollment. Characteristics of HIV-1 infected donors are listed in Table 
2.   
Isolation of resting CD4+ T cells 
Whole blood or leukapheresis blood samples were collected and isolated as described 
previously.7 Briefly, peripheral blood mononuclear cells (PBMCs) were isolated from 
whole blood by density gradient centrifugation. Resting CD4+ T cells (CD4+, CD69-, 
CD25-, HLA-DR-) were enriched using magnetic microbeads through negative depletion 
(Miltenyi Biotec). 
	 15	 	
Drug treatment conditions 
All treatments were performed in basic media (RPMI with 10% fetal bovine serum) 
unless otherwise noted. Drug concentrations were as follows: rapamycin 5.47 µM (5 
µg/ml, rounded to 5 µM) or 547 nM (0.5 µg/ml, rounded to 500 nM) as indicated 
(Millipore, 553211), cyclosporin A 500 nM (Sigma, C3662), bryostatin-1 10 nM (Sigma, 
B7431), romidepsin 40 nM (Selleck Chemicals, S3020). All drug treatments, including 
vehicle alone, had a final DMSO concentration of <.05%. αCD3/αCD28 treatment was 
set up as follows: 10 µL αCD3 antibody (BD Biosciences, 555366) plus 1 mL PBS each 
was added to wells on a 12 well plate and incubated at 37° C for 1.5 hours. After 
incubation, wells were washed twice with PBS to remove excess antibody. 1 µL αCD28 
antibody (BD Biosciences, 555725) was added per 1 mL media at final treatment. 
Quantification of HIV-1 mRNA transcripts 
All drug treatments were performed in 1 mL media total with duplicate treatments of 
5x106 cells each. RNA isolation and cDNA synthesis were performed as previously 
described7. Real-time PCR was then performed in triplicate using Taqman Fast 
Advanced MasterMix (Life Technologies, 4444556) on an ViiA7 Real-Time PCR System 
(Life Technologies). Primers used were specific for correctly terminated polyadenylated 
HIV-1 mRNA, as described by Shan et al. (46). 
Supernatant cytokine analysis 
Cytokine release was quantified directly from supernatants of cells used for viral RNA 
quantification. Supernatants were collected after 24 hours of drug treatment, when cells 
were used separately for intracellular RNA measurement. Samples were kept at -80 until 
use and then analyzed according to a previously described protocol (2). Supernatant 
cytokines were measured using two kits: CBA Human Th1/Th2/Th17 kit (BD 
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Biosciences, 551811) to quantify 7 cytokines in total, shown are the 4 pro-inflammatory 
cytokines induced to highest levels by αCD3/αCD28 stimulation (IL-2, TNFa, IFNg, IL-6); 
or Human Soluble Protein Master Buffer Kit (BD Biosciences, 558264) with MIP-1a, 
MIP-1b, IL-8, MCP-1, and IL-1b Flex Sets (BD 558325, 558288, 558277, 558287, and 
558279 respectively).  
Cell proliferation assay 
Cellular proliferation was quantified using CellTrace CFSE (Invitrogen, C34554) in 
PBMC derived from healthy donor blood, according to manufacturer’s protocol. Briefly, 
cells were stained for 5 minutes at room temperature with CFSE at a final concentration 
of 5 uM. Cells were washed to remove excess stain, and then treatments set up. After 
treatment, cells were resuspended in PBS and analyzed with a FACSCanto II (BD 
Biosciences). Treatments were set up as follows: 5 million cells per condition, in 
duplicate, for 24 hours at drug concentrations described above. 
Cell death assay 
Cell death was determined in healthy donor PBMC after 24-hour treatment of 5 x 106 
cells per condition using the Zombie Aqua Fixable Viability Kit (Biolegend, 423101) 
according to the manufacturer’s standard cell staining protocol. Briefly, cells were 
stained post-treatment using 1 uL stain per 1 x 106 cells in 100 uL PBS at room 
temperature for 15 minutes. Cells were then washed and dead cells quantified on a 
FACSCanto II. 
Measurement of cell surface markers  
Surface marker expression was determined in healthy donor PBMC 24-hour after 
treatment of 1 million cells per condition. Stains used were: PD-1 PE (BD 560795), CD3 
Pacific Blue (BD 558117), CD4 FITC (BD 555346), CD69 APC-Cy7 (BD 556656), and 
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CD25 APC (BD 555434) according to manufacturer’s protocols. Cells were analyzed by 
flow cytometry using a FACSCanto II. 
CTL coculture 
Whole blood samples from HIV-1 infected individuals were collected and processed as 
described previously (3). Briefly, PBMCs were isolated from whole blood and isolated to 
CD4+ T cells or prestimulated to prime a CD8+ response. Prestimulated PBMC were 
cultured with IL-2 (10 U/ml) with or without a mixture of 129 Gag peptides (80 ng/ml for 
each) (NIH AIDS Reagent Program) for 6 days. Rapamycin (500 uM) was added to 
some PBMC cultures during the last 3 days of prestimulation without media change. 
CD4+ T cells were cultured for 3 days, activated as described in cytokine enriched media 
for an additional 3 days, then infected with NL4-3-Δenv-GFP reporter virus (NIH AIDS 
Reagent Program). Cells remained in cytokine-enriched media for 1 hour before 
washing, replating in basic media, and addition of rapamycin to some cell populations as 
indicated. On the day of coculture, CD8+ T cells were isolated from prestimulated PBMC 
by negative selection (Miltenyi Biotec, 130-096-49). At coculture rapamycin (500 nM) or 
cyclosporin (500 nM) were added to some wells as indicated. Cells were cocultured for 3 
days at a 1:1 effector:target (E:T) ratio before staining with CD8 APC (Biolegend 
300912) and CD3 Pacific Blue (Biolegend 300330) according to the manufacturer’s 
protocol. Samples were read on a FACSCanto II. 
 
Results   
 To determine whether rapamycin affects HIV-1 transcription elicited by T cell 
activation, we treated purified rCD4s from infected individuals on suppressive cART with 
latency reversing stimuli and quantitated changes in HIV-1 gene expression. This 
system more closely approximates the in vivo response than do latency models involving 
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transformed cell lines or primary cells infected in vitro (47). Because the in vivo 
frequency of latently infected cells is low, large numbers of cells must be evaluated with 
sensitive assays for HIV-1 RNA.  We treated aliquots of 5x106 purified rCD4s with T cell 
activating stimuli in the presence of varying concentrations of immunosuppressants to 
determine the concentrations that blocked cytokine production without cellular toxicity. 
After 24 hours, intracellular HIV-1 mRNA was measured by qRT-PCR using primers that 
detect all correctly polyadenylated HIV-1 transcripts (47). At concentrations as low as 50 
nM, cyclosporin inhibited HIV-1 induction by αCD3/αCD28 (Figure 1B) and IL-2 release 
(Figure 1C). In sharp contrast, rapamycin did not produce a dose-dependent inhibition of 
reactivation of HIV-1 from latency even at concentrations as high as 5 µM, despite 
inhibiting IL-2 production at lower concentrations (Figure 1B, 1C). Neither drug affected 
cell viability in the concentration range tested (Figure 1D).  
Using dose-response data from the above experiments and published studies 
(55, 59), we compared the effects of cyclosporin and rapamycin in cells from patients on 
cART by treating 5x106 cells per condition with vehicle alone (DMSO), αCD3/αCD28 
alone, or αCD3/αCD28 plus rapamycin or cyclosporin. HIV-1 mRNA levels increased 
significantly after treatment with αCD3/αCD28 alone for 24 hours (p=0.048, Figure 2A). 
To account for substantial interpatient baseline variability, the data were normalized to 
DMSO control (Figure 3A). We observed no significant difference in HIV-1 RNA 
induction by αCD3/αCD28 with or without co-treatment with 5 µM rapamycin. However, 
cyclosporin significantly suppressed αCD3/αCD28-induced HIV-1 mRNA induction even 
at a 10-fold lower concentration (500 nM) (p=0.003). To rule out effects of 
immunosuppressants on baseline HIV-1 transcription, we treated cells with vehicle alone 
(DMSO), rapamycin, cyclosporin, or αCD3/αCD28 for 24 hours. αCD3/αCD28 
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significantly increased HIV-1 mRNA transcripts (p=0.008), while rapamycin or 
cyclosporin had no effect (Figure 2B). 
We also examined supernatants from the cultures described in Figure 3A for pro-
inflammatory cytokines. IL-2, TNFα, and IFNγ were induced at high levels in rCD4s, 
whereas other cytokines tested were not substantially produced after αCD3/αCD28 
treatment. Co-treatment with αCD3/αCD28 and rapamycin significantly decreased 
release of IL-2, TNFα, and IFNγ compared with αCD3/αCD28 alone in these rCD4s 
(p=0.0009, 0.0002, and 0.019 respectively; Figure 3B-D) Cyclosporin treatment also 
significantly decreased production of these cytokines (IL-2, p=0.001; TNFα, p=0.012; 
IFNγ, p=0.029). Co-treatment also inhibited production of IL-2, MCP-1, MIP-1α, IL-1b, 
MIP-b, IFNγ, TNFα, and IL6 by unfractionated PBMC (Figure 4A). Rapamycin inhibited 
MIP-1α production by over 50% and all other measured cytokines by over 80% (Figure 
4B). This effect was not due to cellular toxicity (Figure 5A).  
 We then measured the effect of each treatment on cell proliferation, another 
potential indicator of clinical toxicity, using a CFSE assay with healthy donor PBMC 
5x106 cells per condition were treated with DMSO alone, αCD3/αCD28, or αCD3/αCD28 
and rapamycin or cyclosporin for 24 hours (Figure 5B). αCD3/αCD28 stimulation caused 
significant proliferation (p=0.014) that was substantially inhibited by rapamycin and 
cyclosporin (p=0.012, 0.018, respectively) (Figure 3E). αCD3/αCD28 treatment strongly 
induced activation marker expression on PBMC from infected individuals after 24 hours. 
Co-treatment with rapamycin decreased expression of CD25 and PD-1 (p=0.024 and 
0.016), as did cyclosporin (CD25, p=0.009 and PD-1, p=0.004) (Figure 5C), suggesting 
that immunosuppressant treatment can downregulate chronic inflammation and T cell 
exhaustion, respectively. Together, these data demonstrate that rapamycin decouples 
latency reversal and cytokine production, allowing maximal HIV-1 induction while 
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preventing toxic consequences of T cell activation. In contrast, cyclosporin was not 
suitable due to inhibition of HIV-1 gene expression. 
 To measure the potential discrepancy between specific inhibition of mTORC1 by 
rapamycin and pan-mTOR inhibition, we also tested mTOR kinase inhibitors Torin1 and 
pp242. mTOR kinase inhibitors downregulate formation of both mTORC1 and mTORC2. 
mTORC2 has a role in the PKC pathway and therefore may interfere with T cell 
activation pathways (56). We found that both of these pan-mTOR inhibitors displayed 
dose-response inhibition of αCD3/αCD28 stimulated HIV-1 expression. pp242 displayed 
significant inhibition of HIV-1 expression, while Torin1 treatment showed a trend toward 
inhibition (Figure 6A-B). 
We next tested the effect of rapamycin on a class of LRAs that may induce some 
level of immune activation: PKC agonists with and without HDACi (10,11). Rapamycin 
did not affect HIV-1 mRNA induction by the PKC agonist bryostatin-1, the HDACi 
romidepsin, or the combination of these (Figure 7A). Shown as fold change, it becomes 
clear that only a modest increase in HIV-1 mRNA was seen with bryostatin-1 or 
romidepsin alone compared to a more substantial induction by the combination (Figure 
7B), consistent with previous reports(47, 63). We also tested the release of cytokines 
suggested to be associated with bryostatin-1 administration in vivo(64). Similar to the 
robust inhibition of PBMC cytokine release induced by αCD3/αCD28 treatment seen 
above, IL-8 and MIP-1α were substantially (>50%) reduced by addition of rapamycin, 
whereas IL-1b, IL-6, and TNFα were not significantly inhibited (Figure 7C). In contrast to 
global immune activation by stimuli including αCD3/αCD28 or PMA/ionomycin, it is 
unclear whether cytokine release is related to in vivo toxicity of bryostatin-1. However, 
these results demonstrate the potential for rapamycin to have a wide applicability to 
different latency reversing approaches. 
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 To further assess the feasibility of rapamycin use in cure strategies, we tested 
whether it affected CTL killing of infected CD4+ T cells using a previously described 
coculture system (detailed setup in Figure 8) (39). Activated CD4+ T cells from infected 
donors were super-infected with an HIV-1 reporter virus expressing GFP (NL4-3-Δenv-
GFP) and then cocultured at a 1:1 effector to target (E:T) ratio with autologous CD8+ T 
cells that had been pre-stimulated with a Gag peptide mixture and IL-2 for 6 days. After 
3 days of coculture, cells were stained with APC-CD8 to excude CD8+ T cells and more 
accurately measure GFP+ CD4+ T cells (gating strategy shown in Figure 5D).  
For each patient, a decrease in GFP+ CD4+ T cells was observed when infected 
CD4+ T cells were cocultured with pre-stimulated CD8+ T cells, compared with infected 
CD4+ T cells cultured alone.  CD8+ T cells pretreated with IL-2 alone caused a less 
substantial reduction in GFP+ cells. Treating the infected CD4+ T cells with rapamycin 
for 24 hours prior to coculture did not prevent CTL killing, showing that epitope 
presentation by infected CD4s was not affected (Figure 9A). We next tested whether 
rapamycin inhibited CTL killing of targets presenting HIV-1 epitopes using the above 
coculture system. Coculture with CD8+ T cells prestimulated with IL-2 plus Gag peptides 
caused significant elimination of GFP+ CD4+ T cells, compared with CD8+ T cells 
prestimulated with IL-2 alone (p=0.047). Rapamycin added at the time of coculture did 
not affect CTL-mediated killing of infected CD4s, whereas cyclosporin had the expected 
inhibitory effect (p=0.027) (Figure 9B). In addition, pre-treatment of CD8+ T cells with 




Overall, our results show that rapamycin inhibits cytokine release and cellular 
proliferation but does not affect HIV-1 latency reversal or CTL mediated killing of HIV-1 
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infected cells. Our CTL data are consistent with previous reports of the effect of these 
immunosuppressants on CTLs (61, 62). Rapamycin has also been suggested as a 
therapeutic in HIV-1 infection, as it downregulates CCR5 and may effectively inhibit viral 
entry of R5 tropic viruses (65). Importantly, pan-mTOR inhibitors downregulate HIV-1 
expression, suggesting the importance of targeting only mTORC1. We found that 
cyclosporin was not suitable for HIV-1 shock-and-kill due to its inhibition of HIV-1 
expression and CTL activity. 
In the search for effective approaches for reactivating latent HIV-1, T cell 
activation continues to be the standard for maximal transcriptional activation of latent 
proviruses. However, compounds that elicit T cell activation markers are often 
overlooked in favor of less effective LRAs. To avoid this compromise, this project has 
explored a latency reversal strategy that allows signaling downstream of TCR stimulation 
to effectively activate HIV-1 gene expression while controlling toxicity by co-treatment 
with the mTOR inhibitor rapamycin. We hypothesize that previously discarded strategies 
eliciting T cell activation could allow for effective reversal of HIV-1 latency in infected 
individuals on effective cART who are also treated with mTOR inhibiting drugs such as 
rapamycin. These findings may allow an expansion in the repertoire of clinically relevant 




Chapter 2: In vivo administration of immunosuppressants to 




Recently, the field of HIV cure research has turned to transplantation as an area 
of interest. The only patient ever cured of HIV-1 infection, the “Berlin patient”, underwent 
allogeneic hematopoietic stem cell transplant (HSCT) to treat a malignancy. The donor 
was homozygous for the CCR5 delta32 mutation, meaning that lymphocytes derived 
from this tissue are resistant to HIV-1 infection due to a deletion in the CCR5 coreceptor 
needed for HIV-1 entry (21). Although a full, sterilizing cure has not been since achieved 
using this strategy, there is still interest in studying HIV-infected individuals requiring 
HSCT to learn more about how we can achieve cure. 
A recent report by Stock et al. (58) presented HIV-1 LR data in patients who 
underwent solid organ transplantation. This type of transplantation is inherently different, 
in that the immune system is not reconstituted post-transplant, and so this approach has 
not gained the same type of interest in the field. Regardless, the study found that there 
may have been a change in the size of the LR based on the immunosuppressant that 
patients received. They reported that HIV-1 infected kidney transplant recipients who 
received rapamycin (sirolimus) for immunosuppression had lower levels of proviral DNA 
in PBMCs compared to HIV-1 infected transplant recipients who received cyclosporin or 
tacrolimus, both calcineurin inhibitors. HIV-1 LR measurements were only measured 
post-transplant; without baseline data, it is difficult to conclude whether there was an 
actual change in the size of the LR. Additionally, PCR for HIV-1 proviral DNA picks up 
many defective HIV-1 proviruses, which make up a large proportion of the LR. Though 
this is not the most sensitive or accurate method of measuring the LR, the study 
interestingly still noted a significant difference that appeared to be immunosuppressant 
dependent. 
Although this method has its caveats, it suggests a reduction in the size of the 
HIV-1 LR in response to rapamycin treatment. The authors suggest that this change may 
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be due to a reduction in chronic immune activation or inflammation characteristic of HIV-
1 infection. It is thought that this inflammation may drive homeostatic proliferation of 
infected cells and perpetuate the LR (66). Alternatively, we propose that the high levels 
of immune activation induced by transplantation (67) could reactivate expression of 
latent HIV-1. Our previous data indicate that HIV-1 transcription could occur in patients 
on rapamycin, allowing elimination of latently infected cells through viral cytopathic 
effects or cell mediated cytotoxicity, leaving rapamycin recipients with a long-term 
reduction in HIV-1 DNA levels. In contrast, HIV-1 gene expression would be inhibited in 
individuals receiving calcineurin inhibitors including cyclosporin or tacrolimus, minimizing 
this potential effect. Our hypothesis explains a difference in the two classes of 
immunosuppressants; if chronic immune activation has a role, it is unclear that mTOR 
inhibition would display more substantial inhibition of activation than calcineurin inhibitors 
would. 
This clinical finding (58) suggests that our above ex vivo results may be 
applicable to HIV-1 infected patients requiring solid organ transplant. We therefore 
chose to expand on these combined findings by measuring the size of the LR before and 
after transplantation, to determine whether there is in fact a reduction in the size of the 
LR in patients receiving rapamycin. In order to get an accurate estimate of the size of the 
LR, we developed a novel assay using a working knowledge of the landscape of the 
HIV-1 latent reservoir and currently available assays. We would also like to compare 
hypotheses and determine whether perturbations of the LR are due to immune activation 
induced by organ transplantation, or a reduction in chronic immune activation due to 
immunosuppressant treatment as proposed by this other group. To specifically rule out 
the other group’s hypothesis, we plan to include measurements of plasma and cellular 
activation markers before and after transplantation. 
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 As the landscape of the LR becomes more fully understood, it has also become 
clear that our ability to accurately measure the LR and to quantify changes after an 
intervention is quite a difficult task. Although only replication competent proviruses able 
to produce infectious viral particles are of importance in a cure strategy, these only 
compromise a small percent of total integrated HIV-1 DNA in rCD4s (41, 68). This is in 
part due to the high mutation rate of HIV-1 reverse transcriptase, which causes the 
proportion of defective proviruses to increase over time (68). These defective proviruses 
further complicate our ability to accurately measure the LR because they have different 
levels of defects: although by definition, none can produce infectious virus, they may still 
undergo transcription, translation and viral peptide production, and even assembly of 
viral particles. Some of these defective proviruses can also be recognized by CTLs and 
targeted during an intervention, further complicating LR measurements (69). This makes 
it difficult to establish a sensitive assay to distinguish intact and defective provirus. 
As explained above, there are three basic types of assays to measure the LR: 
viral outgrowth, PCR for HIV-1 DNA, or PCR for inducible HIV-1 RNA. The quantitative 
viral outgrowth assay (QVOA) is considered to be the most vigorous of these assays, as 
it detects only replication-competent virus (45). It does, however, have some caveats, 
including a requirement of a large blood sample and its time-consuming nature. The 
most serious fallback of this assay may be its small dynamic range; it estimates the 
majority of patients to have 1 infectious unit per million cells (IUPM), while the true 
number of intact proviruses per million may be 30-40 times larger (41, 68). Additionally, 
IUPM estimates from QVOA do not correlate with the number of intact proviruses, 
meaning that QVOA may not be an accurate measurement of latently infected cells that 
are a barrier to cure. For these reasons, we consider QVOA to be a minimal estimate of 
the LR. After an intervention, it may not be the most sensitive way to measure a change 
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in the LR due to its small dynamic range and inability to pick up many cells harboring an 
intact provirus. 
If QVOA is the minimal estimate, then measurement of HIV-1 DNA is the 
maximal estimate of the size of the LR. This method quantifies all cells carrying an HIV-1 
provirus regardless of defective status, as long as primers are compatible with the 
sequence. This estimate is up to 300-fold higher than that predicted by QVOA (44). 
Measuring changes in the LR using this method is also not optimal, because it includes 
many proviruses that will not be eliminated during an intervention. In between these two 
estimates of the LR is PCR for induced HIV-1 RNA. This method restricts detection to 
only transcription-competent HIV-1 proviruses. Interestingly, new data has shown that 
many defective proviruses capable of transcription produce only low levels of HIV-1 RNA 
(69), meaning that use of qPCR may enable a cutoff to increase likelihood of detecting 
intact proviruses. Other defective proviruses capable of higher levels of transcription 
approaching that of intact proviruses are more likely to produce viral peptides, making 
them potential targets in a “shock-and-kill” strategy (69).Therefore, use of qPCR for 
inducible HIV-1 may enable a more accurate estimate of the LR than other methods. 
Although it does not detect only proviruses that pose a barrier to cure, currently available 
assays can be altered to primarily detect viruses that may be targeted during 
intervention.  
 Limiting dilution assays for inducible virus are currently available to estimate the 
size of the HIV-1 LR. Of particular note is TILDA, the tat/rev induced limiting dilution 
assay, which has generated interest due to its small required sample size and minimal 
time requirement. In TILDA, cells are plated at limiting dilution and stimulated for 12 
hours with PMA and ionomycin for maximal induction of HIV-1 RNA. Tat/rev nested 
primer sets for multiply spliced RNA are then used for detection of induced proviruses to 
reduce read-through of RNA transcripts (70). The number of “positive” wells at each 
	 28	 	
dilution can then be used to calculate an estimate of the number of infected cells per 
million. One major caveat of this assay is the use of nested PCR for amplification. This 
PCR method may be necessary due to a combination of the low number of cells used in 
the assay and the lack of an RNA isolation step as a part of the protocol. However, 
nested PCR washes out any potential difference in qPCR readouts, which may be 
important due to the likelihood that defective, transcription competent proviruses will 
produce low levels of RNA (69). An ideal assay would allow distinction of low or high 
levels of viral transcription in each well in order to get a better idea of which proviruses 
are likely to be eliminated during an intervention, and are truly a barrier to cure. We 
sought to improve on this assay by using a different primer set and PCR protocol, using 
a cycle threshold cutoff that would give us a more accurate idea of which proviruses 
were induced to produce high levels of HIV-1 RNA. 
 With knowledge of the landscape of the LR expanding, we felt that the field is 
approaching an assay to more accurately measure the size of the latent reservoir than 
currently available limiting dilution induction assays. An ideal assay should distinguish 
between intact and defective proviruses, but need not necessarily exempt transcription 
or translation competent viruses that can be targeted during a cure intervention. We 
developed the Quantitative Viral Induction Assay (QVIA) to better fit these needs than 
any assays described to date. By using smaller dilutions and more wells than QVOA, it 
has a much higher dynamic range, making QVIA more sensitive to changes in infected 
cells over time. Here we discuss preliminary data distinguishing a qPCR cutoff for 
induced proviruses, intra-assay variability of QVIA, and assessment of clinical samples 





Materials and Methods 
Quantitative Viral Induction Assay (QVIA) 
From PBMC, isolate CD4+ T cells by negative selection. From this population, 
isolate resting CD4+ T cells using CD69, CD25, and HLA-DR negative selection (CD4, 
CD69, CD25, HLA-DR negative isolation kits: Miltenyi 130-096-533, 130-092-355, 130-
092-983, 130-046-101 respectively). Resuspend 4 million resting CD4+ T cells in 3.6 ml 
media (RPMI + 10% FBS). Plate cells on a 96 well round-bottomed plate at serial dilution 
(1:2 dilution from A-H), First, pipette 180 ml original suspension to columns 1-10 in row 
A. Add 1.8 ml fresh media to remaining cells to dilute 1:2 for next row, and repeat 
through row H. This will yield 200K cells in row A, 100K cells in row B, etc. Keep 
columns 11-12 free. (80 wells total). Should have 180 uL total / well to leave space for 
10x drug. Prepare drugs at 10x, including DMSO control. Add DMSO only to column 1; 
PMA and ionomycin to columns 2-10 (PMA 50 ng/ml, ionomycin 1 uM). Treat cells for 18 
hours. 
 Prepare cells for lysis: pellet cells in 96 well plate (1400 RPM for 5 minutes). 
Wash cells with 100ul/well PBS, pellet again. Add 150uL Lysis/Binding Buffer 
(Dynabeads mRNA Direct Purification kit: Thermo Fisher Scientific 61012) to cell pellet 
and pipette to lyse. Option to wrap plate in parafilm and foil and freeze at -80C until 
ready to proceed. 
 To isolate RNA using Dynabeads mRNA Direct Purification kit: Resuspend beads 
thoroughly by vortexing. Transfer beads (10ul beads per well) to microfuge tube and 
place on magnet (30 sec or until solution is clear). Remove supernatant and resuspend 
beads in equivalent volume of fresh Lysis/Binding Buffer. Move cell lysate to a PCR 
plate (200ul well size). Add washed beads to cell lysate: 10 ul/well. Incubate with 
continuous mixing for 3-5 minutes at RT to bind mRNA to beads (longer if viscous). 
Place plate on magnet for 2 minutes, then remove supernatant (10 minutes if viscous). 
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Wash beads 2-3 times with Washing Buffer A (150uL per well per wash). Wash beads 2 
times with Washing Buffer B (150uL per well per wash). Elute in 5-10ul water. RNA 
amples can be stored at -20C. 
 To make cDNA: (qScript Flex cDNA Kit: Quanta Biosciences 95049-100) Keep 
all components (except enzyme) on ice. Assuming 10ul samples) Prepare random 
primer: mix 3ul water + 2 ul random primer / each well. Add 5 ul to each well, mix. 
Incubate 5 min at 65C, snap chill on ice. Prepare reaction mix: 4ul 5x reaction mix + 1ul 
RT. Add 5ul / each well. Incubate 10 min @ 25C, 45 min @ 42C, 5 min @ 85C, hold @ 
4C. Samples can be stored at -20C. 
 Measure induced proviruses per million (IPPM) by qPCR: Prepare qPCR reaction 
mix: 100ul forward primer, 100ul reverse primer, 200ul probe, 1ml FastAdvanced 
Mastermix (Taqman FastAdvanced Mastermix: Life Technologies 4444964; primers 
published (46): Applied Biosciences ViiA7). Add 14ul qPCR reaction mix to every well on 
a 96-well, 100ul qPCR plate. Pipette 6ul cDNA sample to columns 1-10 (corresponding 
to experimental setup). Pipette standard DNA (in duplicate) to columns 11-12 at the 
following copy numbers: 60000, 6000, 600, 300, 150, 60, 30. Remaining 2 wells should 
be no template control. Run according to fast plate protocol for 50 cycles. IPPM can be 
calculated using positive wells measured. 
 
Results 
 We first performed assay optimization and characterization to better understand 
the IPPM readout of QVIA. QVIA requires only 4x106 CD4+ T cells or rCD4s and takes 2 
days from start to finish (Figure 10A). The negative assay frequency is 0.19 induced 
cells per million (IPPM) with a measured frequency range of 0.29 to 1,510.22 IPPM. 
After each qPCR run, a cutoff for “positive” wells can be established by a characteristic 
gap in Ct (cycle threshold) values: anything below this gap is considered “negative”. 
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(Figure 10B-C). Negative wells with low signal can be included in a measurement of 
PPM (proviruses per million), which provides more information about inter-patient 
variability in the LR. 
 We have also begun data collection to assess inter- and intra- assay variability of 
QVIA. To assess intra-assay variability, we isolated bulk CD4+ T cells or rCD4s from 
cART-suppressed individuals and set up QVIA plates from the same blood draw, 
separately. All later steps including lysis, RNA isolation, and cDNA synthesis were also 
completed separately from each other. Our preliminary data indicate that IPPM 
measurements from the same blood draw come out virtually identical (Figure 11A-B). To 
measure our inter-assay variability, we have collected samples from patients at different 
timepoints. The IPPM readouts from these QVIA setups can be compared to measure 
variability over time. 
Next, to measure the HIV-1 LR in patients pre- and post-intervention, we set up 
QVIAs for IPPM measurements in transplant patient samples. All patients were on 
suppressive cART before they received kidney or liver transplantation from HIV+ or HIV- 
donors. 60 ml whole blood was obtained pre-transplant (baseline), and at 13 weeks and 
26 weeks post-transplant for all organ recipients. During processing, plasma samples 
and small amounts (2-3x106) of PBMC were saved for later analysis of immune 
activation or exhaustion markers. Cells were isolated to bulk CD4+ and QVIA setup 
performed on this cell set. Any cells in excess of 4x106 CD4+ T cells were frozen down. 
We found that IPPM measurements significantly increased from baseline to 13 weeks 
post-transplant (p=0.007, Figure 12A, Table 3). We measured a maximum 10-fold 
increase in one patient from baseline to 13 weeks and a mean increase of 10.088. 
Overall, the mean baseline IPPM = 7.689, mean 13-week IPPM = 15.255, mean 26-
week IPPM = 13.593. Only 1 out of 8 patients measured had a decreased IPPM post-
	 32	 	
transplant, from a low value of 1.473 at baseline to 0.0193 (undetectable) at both 13 and 
26 weeks. 
To get an idea for what may cause the increased IPPM, it must first be defined 
whether the measured increase is due to a difference in the number of infected cells, or 
increased “inducibility” of latent proviruses. We can get an idea for this difference by 
looking at the total wells in which RNA was detected in this assay, including those 
considered “negative” in the IPPM readout. This measurement of total proviruses per 
million is termed PPM. We found that there was a close relationship between IPPM and 
PPM, with a relative increase in PPM that matched IPPM increases in most cases 
(Figure 12B). These data represent a relative increase of low copy number wells that 
matched that of positive wells, and seems to suggest a total increase in the number of 
infected cells from these samples. We also measured for viral “blips”, when the viral load 
comes briefly above the clinical limit of detection. Although samples were not obtained 
for all patients at every timepoint, blips were measured in 3 out of 8 of the patients 
studied in the days immediately post-transplantation (Figure 12C).  
 
Discussion 
 Our original hypothesis was for a role of rapamycin treatment in decreased HIV-1 
LR size post solid organ transplant. Instead, we saw the surprising result of increased 
IPPM in most patients at 13 weeks post-transplant. This increase must be better 
characterized: although we saw an increase in the total number of wells containing a 
provirus with any detectable RNA signal, this does not definitively mean that the number 
of infected cells has increased at this timepoint. It is possible that the overall ability of 
latent proviruses to express any RNA increased. This could be explained by an overall 
change in immune activation status in these individuals. The next step is to quantify HIV-
1 proviral DNA at each timepoint using frozen PBMCs from these samples. These 
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patients also need continued followup to measure changes in the LR at 26 months and 
at later times, to characterize whether the trend at 13 weeks holds. There are not 
enough data points to assess a role of immunosuppressant treatment at this time, but it 
will be interesting to see whether this influences is a difference in LR modulation. 
Detection of blips in viral load during this process is potentially consistent with 
our original hypothesis. During latency reversing interventions, blips are often looked for 
because they represent an increase in viral expression during “shock” in shock-and-kill. 
Although samples were not collected every day post-transplant for every patient, we 
were still able to measure blips above the clinical limit of detection in 3 out of 8 of the 
patients. This number represents a much more frequent measurement of blips than is 
typically seen in a clinical setting, where patients are adherent to cART. The next step 
for these samples will be to sequence virus from these blips to characterize what is 
being reactivated and compare these sequences to what is activated in QVIA at different 
timepoints. 
To further our knowledge of the landscape of the latent reservoir, it is important 
to also consider other compartments harboring latently infected cells, including the 
lymph nodes. Lymph nodes have been suggested as “sanctuary” locations, where cells 
may not be exposed to high enough levels of cART to prevent viral replication (71). HIV-
1 RNA in the lymph nodes versus peripheral blood have only been quantified previously 
in untreated patients, and no difference was measured (72). It is important to the field to 
do an updated study characterizing potential viral evolution and differences in the 
proportion of infected cells in the lymph nodes compared with peripheral blood in 
patients on suppressive ART. Lymph node mononuclear cells (LNMCs) were collected 
from patients during transplantation, and are comparable to baseline blood samples. We 
can compare QVIA readouts and subsequent viral sequencing data in from PBMC and 
LNMC in order to get a more complete, unprecedented scope of the LR.  
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 Characterization of QVIA is still in preliminary stages. We are currently working to 
sequence mRNA from positive wells. Our current hypothesis is that wells with higher 
copy number, considered to be “positive wells”, have a higher probability of expressing 
intact or translation-competent provirus than do low copy number wells below the qPCR 
cutoff. It is likely that wells with lower RNA expression have 5’ deletions, since our 
primers detect at the far 3’ end of HIV-1 mRNA. If this pattern holds true, this aspect of 
QVIA could make it more appealing for use than other limiting dilution PCR based 
methods to measure the LR. We must also continue to assess the inter- and intra- assay 
variability of QVIA in order to establish it as a consistent, accurate assay. 
 QVIA can also be used to quantify the number of cells that respond to a stimulus, 
and at what level on an individual cell basis. In most ex vivo assays, the response of 
rCD4s derived from HIV-1 infected individuals is measured by pooling large numbers of 
cells prior to stimulation (47). This setup increases the probability of including an equal 
number of latently infected cells in each treatment condition in order to minimize 
variation. Although this strategy for comparing the latency reversing potential of agents 
is effective on an overall quantitative scale, it does not give any information about 
whether higher amounts of HIV-1 RNA in response to a stimulus represent higher 
amounts of transcription, or a larger quantity of cells responding. QVIA can easily be set 
up with stimuli other than PMA and ionomycin in order to compare strategies and 
measure this discrepancy. This data would give us more information about the potential 
efficacy of various LRAs: the best latency reversing agents would maximize number of 
cells with induced HIV-1 expression in order to increase the potential to eliminate 
infected cells. 
We would also like to know whether IUPM readouts from QVOA correlate with 
QVIA IPPM measurements. These two assays are measuring different aspects of the 
LR: QVOA only picks up intact, replication competent proviruses expressed in response 
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to PHA stimulation. QVIA measures all latent proviruses capable of high levels of 
transcription. Although the former represents the true barrier to a cure for HIV-1 
infection, it also fails to measure many intact, potentially infectious viruses. Conversely, 
QVIA will measure some proviruses that are not a true barrier to cure, but will still 
represent a population of proviruses enriched for those that will be targeted during a 
cure intervention. Thus, we propose that QVIA will still give an accurate idea of changes 
in the LR during an intervention, but may not correlate with QVOA readouts. It might be 





Chapter Three: Elucidating the mechanism of HIV-1 latency 




Although T cell activation produces the most robust reactivation of latent HIV-1 
expression of any studied technique, the field has also explored several other more 
targeted methods for activating HIV-1 expression. Classes of small molecules that can 
effectively activate HIV-1 transcription in latently infected cells from HIV-1 infected 
patients have been identified and are candidates for clinical use (33). Before many of 
these compounds were tested using primary cells, they were identified in cellular models 
designed to recapitulate latency. However, not only do many of these compounds 
activate latency more robustly in models than in primary cells, it also became apparent 
that many other compounds identified as “hits” in model cell screens did not have any 
effect in either primary cells or in patients (47). Although this phenomenon has been 
demonstrated using multiple compounds, there has been little work questioning the 
discrepancy between these systems. Here we identify pathways varying between 
primary rCD4 and our lab’s bcl-2 transduced cell model of latency at baseline and in 
response to LRA stimulation to study additional unknown blocks to HIV-1 transcription in 
HIV-1 latency. 
Of the identified latency reversing agents (LRAs), many have a proposed 
mechanism of action by which they specifically reactivate latently HIV-1 expression. 
However, these mechanisms remain somewhat controversial and require further 
investigation. Histone deacetylase inhibitors (HDACis) are a class of LRAs with a vague 
mechanism unsupported by empirical evidence associated with their activity on HIV-1. 
HDACis are a broad class of drugs with relevance to certain cancer types. Several, 
including vorinostat, panobinostat, and romidepsin have FDA approval to treat 
lymphoma and myeloma diagnoses. They do have activity on histones, inhibiting their 
deacetylation and the increasing overall transcription state in a cell. HDACis have 
several activities that are thought to be relevant to their cancer killing potential, including 
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direct non-histone related activity on transcription factors, structural proteins, and 
chaperones; and activity on cell cycle, apoptosis, and DNA damage pathways directly 
downstream of histone activity (73). HDACi activity on latent HIV-1 reactivation has been 
classically attributed to a simple, direct activity of these drugs on histones associated 
with the HIV-1 LTR promoter (74). It is thought that HDACi allow for a more permissive 
transcriptional state, promoting HIV-1 gene expression. 
A study examining the latency reversal activity of the HDACi vorinostat in HIV-
infected individuals exemplifies the lack of support for this mechanism (75). In this study, 
several HIV-1 infected individuals on suppressive cART were given vorinostat to test its 
in vivo latency reversal and potential activity on the latent reservoir. In this trial, they 
collected samples from patients at several timepoints, and measured various activities of 
vorinostat including changes in histone acetylation state and HIV-1 cell-associated RNA. 
Although the authors assume that increases in histone acetylation caused by the direct 
HDACi activity of vorinostat is allowing for more permissive transcription, and therefore 
higher levels of HIV-1 RNA expression, their own data has a chronological contradiction: 
they show that histones in lymphocytes have peak acetylation between 8-24 hours after 
vorinostat treatment, declining after 7-14 days. However, peak measurements in cell-
associated HIV-1 RNA were not measured in most (18/19) patients until at least 7 days 
after vorinostat administration, and as much as 84 days in some patients (75). Because 
this increase in HIV-1 expression seems to continue long after a decline in histone 
acetylation status, it seems that the latency reversing activity of HDACi may be 
explained by one of the many other activities of this class of drug. 
Here we perform gene expression and transcription factor screens, identifying 
“hits” by comparing baseline expression and differences in response to stimulation with 
HDACi in our model system and in primary cells. After performing preliminary 
experiments using a combination of LRAs and specific pathway inhibitors, we identified 
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p21 as a continuing pathway of interest, and continue our focus on a role for p21. 
Although HDACi do not have a well-characterized mechanism of action as LRAs, they 
are known to have substantial activity upregulating p21 gene expression. In fact, in the 
above study where patients were administered vorinostat, CDKN1A/p21 was one of the 
genes that was shown to be overexpressed, as a proof-of-concept that the treatment 
had the expected effect (75). 
p21 is a small protein that promotes G1 arrest in response to many stimuli 
including cellular stress, DNA damage, and cytokine signaling. Transcription of the p21 
gene is directly downstream of p53 signaling (76). The p21 protein is known to have a 
role during initial HIV-1 infection, when it associates with Vpr to induce cell cycle arrest 
(77). p21 expression has not been implicated in HIV-1 infectivity, but because it is 
specifically overexpressed during infection, it is possible that it has a role in facilitating 
HIV-1 expression to perpetuate infection. If this is true, it would logically follow that 
upregulation of p21 during a latency reversal strategy would upregulate HIV-1 gene 
expression. 
We therefore followed up on p21 by studying the effects of p21 modulators on 
the activity of HDACi on both HIV-1 expression and on p21 protein expression. We 
indirectly attempted to downregulate p21 activity by upregulating p27, another protein 
involved in cell cycle regulation that typically has reciprocal activity from p21. We also 
looked for an effect of these modulators on the PKC agonist bryostatin, which displays 
synergy with HDACi: if p21 is important in the HIV-1 latency reversal potential of HDACi, 






Materials and Methods 
Isolation of resting CD4+ T cells 
Whole blood samples were collected and isolated as described previously (47). Briefly, 
peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by density 
gradient centrifugation. CD4+ T cells were enriched using magnetic microbeads through 
negative depletion (Miltenyi Biotec). Where indicated an additional enrichment was 
performed to isolate resting CD4+ T cells (CD69-, CD25-, HLA-DR-). 
bcl-2 transduced cell model for HIV-1 latency 
Model cells were produced as previously described (78). Briefly, primary CD4+ T cells 
were isolated from healthy HIV- donors, activated, and transduced with a lentiviral 
construct containing a constitutively active bcl-2 gene. These cells were cultured for 4 
weeks to enrich for immortalized cells, then again activated, expanded, and infected with 
a single-round infection lentiviral vector with GFP driven by the HIV-1 promoter. Cells 
were cultured for 6 weeks to allow a return to resting state so cells may become “latent”, 
as defined by GFP- status that may revert to GFP+ upon stimulation. 
qPCR array 
The qPCR array data was collected using the Human Stress & Toxicity PathwayFinder 
RT² Profiler PCR Array (SABiosciences) according to the manufacturer’s protocol. 
Briefly, RNA was isolated from samples and cDNA made according to an above 
protocol. Total cDNA was then mixed with the RT2 qPCR mastermix, and added to a 96-
well plate that already contained primers a given target in each well. qPCR was then 
performed on an AB ViiA7 instrument, and analyzed using the manufacturer’s data 




Transcription factor profiling array 
To assess transcription factors that were differentially regulated by different cell types at 
baseline and upon stimulation, we used TF Activation Profiling Plate Array II (Signosis) 
according to the manufacturer’s protocol. Briefly, specific DNA probes bound to biotin 
are combined with nuclear extract from the sample. After incubation the sample is 
column separated to remove free probe, and then probes with bound activated 
transcription factors can hybridize to wells containing specific complementary DNA to 
each probe in a 96-well plate. The sample is then incubated with streptavidin-HRP, a 
chemiluminescent substrate, and read with a luminometer. This kit allows for comparison 
of 96 transcription factors between conditions. 
Drug treatments 
All treatments were performed in basic media (RPMI with 10% fetal bovine serum) 
unless otherwise noted. Drug concentrations were as follows: romidepsin 40 nM (Selleck 
Chemicals, S3020), panobinostat 30 nM (Selleck Chemicals, LBH589), bryostatin 10 nM 
(Sigma-Aldrich, B7431), disulfiram 500 nM (Sigma-Aldrich, D2950000). Inhibitors were 
used at their known IC50 values: UC2288 (EMD Millipore, 5328130001), SKPin C1 
(R&D Systems, 4817). All drug treatments, including vehicle alone, had a final DMSO 
concentration of <.05%.  
Measurement of intracellular p21 protein levels 
Cells were fixed and permeated using Cytofix/cytoperm kit (BD Biosciences, 554714) 
before intracellular staining for FACS analysis. Briefly, cells were washed then 
resuspended in 100µl Fix solution per well, and incubated for 20 minutes at 4°C 
protected from light. After this incubation, supernatants were removed and cells were 
resuspended in 1x perm wash solution with a 1:200 dilution of the 1° rabbit anti-p21 
antibody (Abcam, ab109520). Cells were incubated for 30 minutes at 4°C with the 
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primary antibody. After this incubation, the 2° goat anti-rabbit IgG antibody (Abcam, 
ab150077) was added at a 1:200 dilution and again incubated 30 minutes at 4°C 
protected from light. Control samples were stained with 2° antibody only, or a rabbit 
polyclonal isotype control (Biolegend, 910801) and 2° antibody to confirm specificity of 
staining.  Cells were then washed 2x with perm wash solution to prepare samples for 




 To first determine the fundamental differences between model cells and primary 
cells, we compared fresh rCD4s with bcl-2 transduced model cells. 2x106 cells were 
treated with DMSO alone (baseline) or various LRAs: romidepsin, panobinostat, 
bryostatin, bortezomib, or disulfiram. After a 24 hour treatment, cells were lysed, RNA 
isolated, and cDNA prepared. cDNA from these samples was used in a Cell Stress and 
Toxicity qPCR array, which was used to generate datasets from 3 sets of model cells, 
associated rCD4s, and drug treatments comparing the differences at baseline and post-
LRA treatment. We found that several genes (GADD45G, CDKN1A, BBC3 and VEGFA) 
were upregulated and some (EDN1, TLR4, and IL1B) downregulated at least 5-fold in 
model cells at baseline compared with rCD4s (Figure 13). By far the most striking of 
these baseline differences was CDKN1A, the gene that encodes for the cell cycle 
regulator p21, which was upregulated 15-400-fold. Interestingly, when rCD4s were 
treated with LRAs of different classes, we saw a similar effect: all treatments upregulated 
CDKN1A gene expression more than 15-fold. 
 To further our knowledge of the differences between rCD4s and model cells, we 
performed a similar comparison using an array measuring activation of various 
transcription factors. In these experiments, 5x106 cells were treated for 72 hours with 
	 43	 	
DMSO alone or various LRAs. We then performed a nuclear extraction, and incubated 
the nuclear extract with DNA sequences that activated transcription factors will 
specifically bind. The assay is qualitative and readouts of an array of factors are 
normalized for intra-sample comparison. Although each batch of model cells tested 
revealed different pathways of interest, some factors fit in well with our previous gene 
expression array data (Figure 14). The transcription factor screen showed increased 
NFAT, NFkB, Sp1, WT1, and p53 expression at basal levels in one batch of model cells. 
Factors overexpressed in both model cell batches included HSF1, NRF1, FOXO1, and 
MEF1. 
 We then performed experiments using specific pathway inhibitors in combination 
with HDACi to identify a potential role for our hits: p21, FOXO1, HSF1, and p53. These 
experiments were done in the J-lat 10.6 cell line, which has an HIV-1 LTR driving GFP 
expression (79). J-Lats have low expression of GFP at baseline that increases with LTR 
activity. We found that the specific p21 inhibitor, UC2288, displayed drastic inhibition on 
romidepsin induced GFP expression in J-Lats (Figure 15A). SKPin C1, an E3 ligase 
inhibitor that upregulates p27 expression and may thereby downregulate p21, also 
modestly downregulated LRA mediated GFP expression (Figure 15B). FOXO1 inhibition 
did not have a drastic effect on GFP expression (Figure 15B). Co-treatment with 
KRIB11, a heat shock pathway inhibitor, downregulated GFP expression in response to 
LRA treatment. However, this inhibition was most substantial on bryostatin-induced GFP 
expression (Figure 15C), and we chose to instead explore mechanisms of action of 
HDACi since these are not as well-characterized. 
The inhibitor data in J-Lats indicated that p21 was the most promising of hits. We 
therefore continued this study to specifically characterize a role of p21 in HDACi activity 
on HIV-1 latency reversal. As a proof-of-concept we first measured p21 activity in rCD4s 
at baseline and with 48-hour treatment with romidepsin or panobinostat, both potent 
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HDACi. We found that treatment with either HDACi or with the potent T cell activator 
PMA/ionomycin substantially increased p21 expression (Figure 16B). In J-Lats, UC2288 
caused substantial inhibition of GFP expression stimulated by various LRAs. In cells 
derived from HIV-1 infected patients, this effect was less substantial, likely due to the low 
activity of single LRAs on cells treated ex vivo (Figure 16A).  However, p21 
downregulation caused inhibition of HIV-1 expression by the potent combination of 
bryostatin and romidepsin, suggesting a role for p21. We measured the expected effect 
of p21 protein downregulation by UC2288 co-treatment (Figure 16B). 
 We next wanted to see if p21 overexpression would have an effect on the HIV-1 
latency reversing potential of HDACi or the PKC agonist bryostatin. To modulate p21 
expression, we used the ubiquitin E3 ligase inhibitor SKPin C1, which has been shown 
to upregulate p27 and so may downregulate p21 protein levels (80). In J-Lats, SKPin C1 
appeared to modestly decrease GFP expression. Conversely, in patient cells, we found 
that SKPin C1 showed substantial synergy with LRAs of all classes to promote HIV-1 
expression (Figure 16A). This drug did not have the expected effect of increasing p21 
expression (Figure 16B). 
 
Discussion 
We sought to determine the fundamental differences between model cells and 
primary cells, in order to better understand the discrepancy in latent HIV-1 reactivation 
between these systems and attempt to harness the differences in pathway expression to 
build a better LRA. Comparing these two cell types gave us a direct comparison of the 
pathways changed during the process of producing model cells while removing donor 
variability by receiving primary cell samples from the same, original donor of model cells. 
We added another layer to this comparison by treating both cell types with various LRAs, 
as well as comparing differences at baseline. We found that CDKN1A, the p21 gene, 
	 45	 	
was overexpressed in model cells at baseline and also increased in response to LRA 
stimulation. We also measured increased WT1 and p53 transcription factor activity in 
model cells. Both these factors positively regulate p21 (76). Overall, these data sets 
suggested a followup on activity of p21 in HIV-1 latency reversal. Since HDACi are well 
characterized to upregulate p21 gene expression, and do not have a supported 
mechanism of action on HIV-1 activity, we chose to specifically study the role of p21 in 
HDACi latency reversing potential. 
In support of our hypothesis, the p21 inhibitor UC2288 did downregulate the 
latency reversing potential of HDACi in J-lats and the combination of the HDACi 
romidepsin with bryostatin in patient cells. All single LRAs only had modest effect on 
HIV-1 expression in ex vivo treated rCD4s, whereas a combination of the PKC agonist 
bryotatin with romidepsin caused more robust HIV-1 expression, consistent with 
previous reports (47, 63). It is likely because of the scale of this effect that we were 
unable to measure downregulation by UC2288 on single LRAs. Our results displaying 
substantial synergy of the E3 ligase inhibitor SKPinC1 with LRA treatment were 
unexpected, and need to be followed up on. The first step would be to test protein 
targets of this E3 ligase including p21 for LRA activity. We also need to confirm that p21 
is in fact downregulated by SKPin C1 treatment, as p21 data from J-Lats and patient 
cells were inconsistent with each other. 
To follow up on a role for p21 in HDACi activity, specific knockdown or 
overexpression experiments can be performed. Transfection with RNAi or CRISPR 
constructs can be used to downregulate p21 expression without off-target effects that 
may be present during treatment with drugs such as UC2288 or SKPin C1. If p21 has a 
specific role in HDACi activity, downregulation of this protein (confirmed by staining) 
should abrogate their effect on HIV-1 expression. p21 can also be upregulated by RNAi 
or CRISPR knockdown of upstream inhibitors, however this strategy is less targeted and 
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may affect other pathways. We have not yet used these approaches, as transfection is 
difficult in unactivated primary cells and can cause high levels of cellular toxicity. 
Our qPCR and transcription factor screens display good validity, in that many 
transcription factors and pathways implicated in our screen have been previously 
suggested to play a role in HIV-1 expression or latency reversal. This includes the 
factors Sp1, NFAT, NFkB, and Hsf1 (53, 81). Other “hits” from our original screen can be 
followed up on in patient rCD4s, as these may respond differently than cell lines such as 
J-Lats. Often cell lines have many dysregulated genes, including proto-oncogenes or 
those involved in cell cycle arrest like p21, so any genes in these categories may be 
particularly important to test in primary cells. For these reasons, it might be most useful 
in the future to directly screen inhibitors in primary rCD4s. 
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Table 1: Definitions and examples of cure. 
Cure type Definition Examples 
Sterilizing 
cure 
Complete eradication of 
replication-competent 
HIV-1 
Berlin patient – following bone marrow 
transplant from a CCR5 delta32/delta32 
donor, cART treatment was stopped and 




Reduction of HIV-1 
reservoir sufficient to 
greatly increase time to 
viral rebound when 
treatment is stopped 
Boston patients – 2 individuals who 
received bone marrow transplants and 
achieved complete chimerism with no 
detectable HIV, but rebounded 3 and 8 
months after cART interruption 
 
Mississippi baby – perinatally infected 
infant with high viremia at birth, began 
cART very early with later discontinuation 




Immune control over 
HIV-1 infection; does not 
necessarily require 
reduction or elimination 
of HIV-1 reservoirs 
Elite controllers – individuals who 
maintain undetectable viral load without 
cART due to unique immune control over 
HIV 
 
VISCONTI cohort – cART initiation during 
acute infection may have induced immune 
control in some patients, who maintain low-




Table 2: Characteristics of HIV-1 infected participants. 
patient 
number 
age gender race time on suppressive 
ART (months) 
cART regimenA 
1 52 M B 36 3TC, RAL, DRV/r 
2 67 M B 32 EFV, 3TC, ABC 
3 49 M W 25 FTC, TDF, EFG/c 
4 55 M B 26 FTC, RAL, DRV/r 
5 52 F B 102 EFV, FTC, TDF 
6 56 M B 24 FTC, TDF, DTG 
7 55 F B 19 FTC, TDF, EVG/c 
8 59 M B 21 FTC, TDF, RAL 
9 53 F B 11 FTC, TDF, ATV/r 
10 49 M unknownB 23 3TC, RAL, DRV/r 
11 62 M B 100 FTC, DTG, DRV/r 
12 34 F B 133 FTC, TDF, EFV 
13 50 M B 40 FTC, TDF, ATV/r 
14 48 F B 49 FTC, TDF, EVG/r 
15 48 F B 90 3TC, ABC, DTG 
16 56 M B 52 EFV, FTC, TDF 
18 64 M B 12 3TC, RPV, RAL 
19 53 M B 20 FTC, TDF, RAL 
20 45 F B 39 FTC, TDF, RAL 
21 43 M B 78 EFV, FTC, TDF 
22 65 F B 123 FTC, TDF, RPV 
23 69 M B 10 3TC, ABC, DTG 
24 50 M W 155 3TC, ABC, RAL 
25 62 M B 70 3TC, ABC, TDF 
26 53 M B 18 EFV, FTC, TDF 
27 37 M B 98 FTC, TDF, RPV 
28 49 M B 93 FTC, TDF, RPV 
29 44 M W 57 3TC, ABC, ATV/r 
30 44 M B 113 3TC, ABC, DTG 
AAbbreviations: abacavir (ABC), emtricitabine (FTC), lamivudine (3TC), tenofovir 
disproxidil fumarate (TDF), efavirenz (EFV), ritonavir-boosted atazanavir (ATV/r), 
ritonavir-boosted darunavir (DRV/r), cobicistat-boosted elvitegravir (EVG/c), raltegravir 




Figure 1: Immunosuppressant mechanisms and dose-response inhibition of HIV-1 or 
cytokine expression by rapamycin or cyclosporin treatment  
A: Accepted mechanisms of action and downstream effects of rapamycin and 
cyclosporin. 
B: RT-qPCR measurements of intracellular HIV-1 mRNA from infected individual derived 
rCD4s, shown as percent inhibition of αCD3/αCD28 induced HIV-1 expression by 
rapamycin or cyclosporin co-treatment. 
C: Dose-dependent inhibition of αCD3/αCD28 induced supernatant IL-2 by increasing 
concentrations of rapamycin or cyclosporin. 
D: Effects of rapamycin or cyclosporin viability of rCD4s stimulated with αCD3/αCD28, 
compared with αCD3/αCD28 treatment alone or unstimulated cells. 























































































































Figure 2: RT-qPCR results for various immunosuppressant treatments. 
A: RT-qPCR results for intracellular HIV-1 mRNA in rCD4s purified from infected 
individuals on cART. Copy number represents copies of HIV-1 mRNA detected per 
million cells. Symbols represent results from different donors (n=10).  
B: Intracellular HIV-1 mRNA levels from cells treated with immunosuppressants alone. 
Results are shown as fold change over the no stimulation control. Dotted line represents 
no change from baseline (DMSO alone). Each symbol represents results from a different 
donor (n=6). 
Data points are the average of duplicate experiment conditions. Error bars represent 






































































Figure 3: Effects of immunosuppressants on αCD3/αCD28 mediated HIV-1 expression 
and pro-inflammatory cytokine release from infected rCD4s. 
A: Relative amounts of induced HIV-1 mRNA shown as fold change relative to no 
stimulation (DMSO alone). All samples represent RT-qPCR measurements of 
intracellular RNA from infected individual derived rCD4s (n=10). 
B: Effect of immunosuppressants on αCD3/αCD28 induced rCD4 production of 
proinflammatory cytokine IL-2.  Points represent supernatant samples from experiments 
described in Figure 2A (n=7). 
C: Effect of immunosuppressants on αCD3/αCD28 induced IFNγ release. (n=7). 
D: Effect of immunosuppressants on αCD3/αCD28 induced TNFα release. (n=7). 
E: Effect of immunosuppressant co-treatment on T-cell proliferation.  Healthy donor 
PBMC (n=3) were stained with CFSE before stimulation. 













































































































































Figure 4: αCD3/αCD28 induced cytokine release by PBMCs is downregulated by 
immunosuppressant treatment. 
A: Quantification of cytokines induced by αCD3/αCD28 alone or cotreatment with 
rapamycin or cyclosporin. Induced cytokines: IL-2, MCP-1, MIP-1a, IL-1b, MIP-1b, IFNg, 
TNFa, IL-6. Bars represent the mean of 3 separate experiments. 
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Figure 5: Immunosuppressant effects on cell surface markers and cell viability; 
representative flow cytometry plots. 
A: Activation and exhaustion cell surface markers. PBMC isolated from patients (n=3) 
were treated for 24 hours for the indicated conditions before cell surface marker 
measurement with flow cytometry. 
B: Effect of immunosuppressant cotreatment on cell viability. PBMC isolated from 
healthy donors (n=4) were treated according 24 hours with the indicated drugs, and 
viability assessed using Zombie Aqua. 
C: Representative example of flow cytometry gating for cellular proliferation analysis. 
Healthy donor derived PBMC (n=3) were stained with CFSE and treated for 24 hours as 
shown. 
D: Representative example of flow cytometry gating for CTL killing assay. Cells were 
cocultured for 3 days then stained with CD8-APC to gate CD4+ T cells (APC-). % GFP+ 
was calculated as a subset of total CD4+ T cells. Fluorescent markers were gated 
against fluorescent channels to exclude autofluorescent cells. 
Data points are the average of duplicate experiment conditions. Error bars represent 






Figure 6: pan-mTOR inhibitors downregulate αCD3/αCD28 mediated HIV-1 expression 
A: Dose-response inhibition of HIV-1 expression shown as fold change to highlight inter-
patient variation. Data points represent duplicate experiment conditions. 
B: Inhibition of αCD3/αCD28 mediated HIV-1 expression by pp242 or Torin1, displayed 
as % max normalized to αCD3/αCD28 alone. (*=p < 0.05, **=p < 0.01) 
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Figure 7: The effect of rapamycin on LRA induction of HIV-1 mRNA and PBMC cytokine 
release. 
A: RT-qPCR measurements of intracellular HIV-1 mRNA in rCD4s purified from infected 
individuals on cART, shown as copies of HIV-1 mRNA detected per million cells. 
Symbols represent results from different donors (n=5). Treatments include bryostatin-1 
(bryo), romidepsin (romi), a combination of bryostatin-1 and romidepsin (bryo/romi), all 
with or without rapamycin. Data points are the average of duplicate experiment 
conditions. 
B: Relative amounts of induced HIV-1 mRNA from A shown as fold change relative to no 
stimulation (DMSO alone). Data points are the average of duplicate experiment 
conditions. 
C: Effect of immunosuppressants on LRA induced production of cytokines by healthy 
donor PBMC. Cytokines shown have been previously suggested to be associated with 
















































LRA bryo bryo romi romi bryo/romi
bryo/
romi
- - -+ + + rapamycin
LRA bryo bryo romi romi bryo/romi
bryo/
romi













bryo bryo romi romi bryo/romi
bryo/
romi























HIV mRNA copy number HIV mRNA fold change
	 57	 	
Figure 8: CTL killing assay schematic 
Whole blood was collected from HIV-1 infected individuals on suppressive cART and 
PBMC purified. PBMC samples were split in half; one half was purified for CD4+ T cells 
and infected with NL4-3-Δenv-GFP for flow cytometry readout. The other half of PBMCs 
was prestimulated with IL-2 alone or plus gag peptide mixture for 6 days, then purified 
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Figure 9: Rapamycin treatment does not reduce CTL killing. 
A: Rapamycin does not affect viral peptide production and presentation of epitopes to 
CTLs (n=3). Activated CD4+ T-cells were infected with NL4-3-Δenv-GFP and cultured in 
media alone, or with rapamycin for 24 hours before coculture. Infected CD4+ were 
cocultured at a 1:1 E:T ratio with CD8+ T-cells prestimulated with IL-2 alone or Gag and 
IL-2. After 72 hours, reduction in infected cells was measured by flow cytometry. 
B: CTL mediated killing of HIV-1 infected cells is impaired by the presence of 
cyclosporin, but not rapamycin (n=8). As above, CD4+ T-cells were infected with NL4-3-
Δenv-GFP. Infected CD4+ were cultured alone, or cocultured at a 1:1 E:T ratio with CD8+ 
T-cells. As indicated, some CD8+ were pre-treated with rapamycin for 3 days before 
coculture, or cocultured in the presence of rapamycin or cyclosporin. 
Data points are the average of duplicate experiment conditions. Two-tailed paired 






















































































Figure 10: QVIA assay schematic and representative qPCR plots 
A: QVIA, the quantitative viral induction assay, requires only 4x106 CD4+ T cells to set 
up. Cells are plated starting at 200K in row A, and subsequently diluted 2x down to row 
H. Columns 11 and 12 are left empty for later qPCR standards. 
B: A representative qPCR amplification plot and standard curve representing QVIA data. 
QVIA readout is characterized by a gap in Ct (cycle threshold) values for at least 2 
cycles. Anything below this gap is considered negative: it is likely either a non-induced 
provirus or a defective provirus that is not fully transcription-competent.  
C: A representative qPCR amplification plot and standard curve representing QVIA data. 



























Figure 11: Measuring the intra-assay variability of QVIA. 
Two plates were set up from the same patient, same blood draw; separately: to measure 
the intra-assay variability of QVIA. Red wells are qPCR positive. 
A. Inducible proviruses per million (IPPM) = 6.654 





Table 3: Transplant patient characteristics. 
IPPM measurements, donor HIV status, transplant type, and date of transplantation for 
patients with 13 and 26-week followup data. 
 
  
patient	ID baseline week	13 week	26 donor	HIV	status transplant	type date	of	transplantation
10577_R 10.634 25.381 37.902 positive liver 3/19/16
83234_R 1.473 0.193 0.193 negative kidney 3/19/16
34246_R 0.858 10.098 2.683 negative kidney 4/19/16
19427_R 34.377 42.62 negative liver 5/9/16
34368_R 5.484 11.238 negative kidney 5/10/16
95475_R 2.318 7.835 negative liver 6/9/16
27098_R 5.496 23.48 positive kidney 7/13/16
83302_R 0.869 1.192 negative kidney 8/3/16
average 7.688625 15.254625
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Figure 12: Transplant patient reservoir measurements 
A: Induced proviruses per million (IPPM) measurements pre-transplant (baseline), and 
13 and 26 weeks post-transplant. 
B: Total proviruses per million (PPM) in each sample from 11A. 
C: Measurements of increases in viral load above the clinical limit of detection (“blips”) 
within 10 days post-transplant. Not all patients or timepoints are represented due to 
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Figure 13: qPCR array heat-map. 
Colors represent differences in gene expression in model cells or in response to LRA 
stimulation in rCD4s. For model cells, changes are shown as model cells/rCD4. For LRA 
conditions, changes are shown as LRA treated/unstimulated. Model cells are 
represented in batches as B1, B2, and B3. Abbreviatations: bortezomib = btz, disulfiram 




Figure 14: Transcription factor array heat map. 
Freshly isolated rCD4s were compared to model cells at baseline and post-LRA 
treatment. Nuclear extracts were used for transcription factor analysis and comparison. 
Blue represents downregulation, orange represents upregulation, and colors darken with 
greater changes. Transcription factors of interest are highlighted. Abbreviatations: 









































































































Figure 15: J-Lat 10.6 cells co-treated with LRAs and modulators of pathways identified 
as “hits”. 
A: Co-treatment of HDACis panobinostat or romidepsin with UC2288, a specific p21 
inhibitor. 
B: Treatment of J-Lats with LRAs alone or with SKPin C1, a p27 activator, or a specific 
FOXO1 inhibitor. 
C: J-Lats treated with LRAs with or without KRIB11, an inhibitor of the heat shock 




















































































Figure 16: HIV-1 mRNA and p21 expression analysis in ex vivo treated rCD4s. 
A: SKPinC1 exhibits synergy with single LRA treatment; UC2288 inhibits HIV-1 
expression in response to a combination of bryostatin and romidepsin treatment. 
Treatments were done on rCD4s from HIV-1 suppressed patients; data points represent 
duplicate experiment conditions. 
B: UC2288 and SKPinC1 downregulate p21 expression in rCD4s. Data points represent 




















































1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on 
combination antiretroviral therapy in high-income countries: a collaborative analysis of 
14 cohort studies. Lancet. 2008 Jul 26;372(9635):293-9. 
2. Neaton JD, Babiker A, Emery S, Gordin F, Lundgren J. Strategic Timing of 
Antiretroviral Treatment (START). Bethesda (MD): National Library of Medicine (US). In 
press 2009.  
3. Al-Dakkak I, Patel S, McCann E, Gadkari A, Prajapati G, Maiese EM. The impact of 
specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a 
systematic review and meta-analysis. AIDS Care. 2013;25(4):400-14. 
4. Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, et al. 
Adherence-resistance relationships for protease and non-nucleoside reverse 
transcriptase inhibitors explained by virological fitness. AIDS. 2006 Jan 9;20(2):223-31. 
5. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during 
chronic HIV infection. Immunity. 2013 Oct 17;39(4):633-45. 
6. Harrigan PR, Whaley M, Montaner JS. Rate of HIV-1 RNA rebound upon stopping 
antiretroviral therapy. AIDS. 1999 May 28;13(8):F59-62. 
7. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 
infection. Annu Rev Med. 2002;53:557-93. 
8. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of 
HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med. 
1995 Dec;1(12):1284-90. 
9. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. 
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. 
Science. 1997 Nov 14;278(5341):1295-300. 
10. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral 
dynamics in human immunodeficiency virus type 1 infection. Nature. 1995 Jan 
12;373(6510):117-22. 
11. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay 
characteristics of HIV-1-infected compartments during combination therapy. Nature. 
1997 May 8;387(6629):188-91. 
12. Siliciano RF, Greene WC. HIV latency. Cold Spring Harb Perspect Med. 2011 
Sep;1(1):a007096. 
	 71	 	
13. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-
term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting 
CD4+ T cells. Nat Med. 2003 Jun;9(6):727-8. 
14. Crooks AM, Bateson R, Cope AB, Dahl NP, Griggs MK, Kuruc JD, et al. Precise 
Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. J 
Infect Dis. 2015 Apr 15. 
15. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, et al. 
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly 
active antiretroviral therapy. Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9403-8. 
16. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, et al. The effect of 
raltegravir intensification on low-level residual viremia in HIV-infected patients on 
antiretroviral therapy: a randomized controlled trial. PLoS Med. 2010 Aug 
10;7(8):10.1371/journal.pmed.1000321. 
17. Hill AL, Rosenbloom DI, Fu F, Nowak MA, Siliciano RF. Predicting the outcomes of 
treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci U S A. 2014 Sep 
16;111(37):13475-80. 
18. Dieffenbach CW, Fauci AS. Thirty years of HIV and AIDS: future challenges and 
opportunities. Ann Intern Med. 2011 Jun 7;154(11):766-71. 
19. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. 
Immunity. 2012 Sep 21;37(3):377-88. 
20. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous 
defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals 
to HIV-1 infection. Cell. 1996 Aug 9;86(3):367-77. 
21. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, et al. Long-term 
control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009 
Feb 12;360(7):692-8. 
22. Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH, et al. 
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell 
transplantation: report of 2 cases. Ann Intern Med. 2014 Sep 2;161(5):319-27. 
23. Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M,Jr, Chun TW, et al. Absence of 
detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013 Nov 
7;369(19):1828-35. 
24. Luzuriaga K, Gay H, Ziemniak C, Sanborn KB, Somasundaran M, Rainwater-Lovett 
K, et al. Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J 
Med. 2015 Feb 19;372(8):786-8. 
	 72	 	
25. Martinez-Bonet M, Puertas MC, Fortuny C, Ouchi D, Mellado J, Rojo P, et al. 
Establishment and replenishment of the viral reservoir in perinatally HIV-1-infected 
children initiating very early antiretroviral therapy. Clin Infect Dis. 2015 Jun 10. 
26. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an 
inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad 
Sci U S A. 1997 Nov 25;94(24):13193-7. 
27. Buckheit RW,3rd, Allen TG, Alme A, Salgado M, O'Connell KA, Huculak S, et al. 
Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor 
transmission pairs. Nat Commun. 2012 Mar 6;3:716. 
28. Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, Lai J, et al. Isolation and 
characterization of replication-competent human immunodeficiency virus type 1 from a 
subset of elite suppressors. J Virol. 2007 Mar;81(5):2508-18. 
29. Metcalf Pate KA, Pohlmeyer CW, Walker-Sperling VE, Foote JB, Najarro KM, Cryer 
CG, et al. A Murine Viral Outgrowth Assay to Detect Residual HIV Type 1 in Patients 
With Undetectable Viral Loads. J Infect Dis. 2015 Apr 15. 
30. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, et al. 
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and 
peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A. 2007 
Apr 17;104(16):6776-81. 
31. Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, et al. HLA class I-
restricted T-cell responses may contribute to the control of human immunodeficiency 
virus infection, but such responses are not always necessary for long-term virus control. 
J Virol. 2008 Jun;82(11):5398-407. 
32. Deeks SG. HIV: Shock and kill. Nature. 2012 Jul 25;487(7408):439-40. 
33. Xing S, Siliciano RF. Targeting HIV latency: pharmacologic strategies toward 
eradication. Drug Discov Today. 2013 Jun;18(11-12):541-51. 
34. Manson McManamy ME, Hakre S, Verdin EM, Margolis DM. Therapy for latent HIV-1 
infection: the role of histone deacetylase inhibitors. Antivir Chem Chemother. 2014 Jan 
29;23(4):145-9. 
35. Bartholomeeusen K, Fujinaga K, Xiang Y, Peterlin BM. Histone deacetylase 
inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) 
from its inhibitory complex also activate HIV transcription. J Biol Chem. 2013 May 
17;288(20):14400-7. 
36. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, et al. Histone 
deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on 
suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS 
Pathog. 2014 Apr 10;10(4):e1004071. 
	 73	 	
37. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. 
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. 
Nature. 2012 Jul 25;487(7408):482-5. 
38. Cillo AR, Sobolewski MD, Bosch RJ, Fyne E, Piatak M,Jr, Coffin JM, et al. 
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on 
suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2014 May 
13;111(19):7078-83. 
39. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, et al. Stimulation of 
HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after 
virus reactivation. Immunity. 2012 Mar 23;36(3):491-501. 
40. Siliciano JD, Siliciano RF. Enhanced culture assay for detection and quantitation of 
latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-
infected individuals. Methods Mol Biol. 2005;304:3-15. 
41. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, et al. 
Replication-competent noninduced proviruses in the latent reservoir increase barrier to 
HIV-1 cure. Cell. 2013 Oct 24;155(3):540-51. 
42. Rouzioux C, Melard A, Avettand-Fenoel V. Quantification of total HIV1-DNA in 
peripheral blood mononuclear cells. Methods Mol Biol. 2014;1087:261-70. 
43. Strain MC, Lada SM, Luong T, Rought SE, Gianella S, Terry VH, et al. Highly 
precise measurement of HIV DNA by droplet digital PCR. PLoS One. 2013;8(4):e55943. 
44. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative 
analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 2013 
Feb;9(2):e1003174. 
45. Laird GM, Eisele EE, Rabi SA, Lai J, Chioma S, Blankson JN, et al. Rapid 
quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS 
Pathog. 2013;9(5):e1003398. 
46. Shan L, Rabi SA, Laird GM, Eisele EE, Zhang H, Margolick JB, et al. A novel PCR 
assay for quantification of HIV-1 RNA. J Virol. 2013 Jun;87(11):6521-5. 
47. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo 
approaches distinguish effective and ineffective single agents for reversing HIV-1 latency 
in vivo. Nat Med. 2014 Apr;20(4):425-9. 
48. Prins JM, Jurriaans S, van Praag RM, Blaak H, van Rij R, Schellekens PT, et al. 
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients 
on potent antiretroviral therapy. AIDS. 1999 Dec 3;13(17):2405-10. 
49. Spivak AM, Planelles V. HIV-1 Eradication: Early Trials (and Tribulations). Trends 
Mol Med. 2016 Jan;22(1):10-27. 
	 74	 	
50. Isakov N, Altman A. Protein kinase C(theta) in T cell activation. Annu Rev Immunol. 
2002;20:761-94. 
51. Stach CS, Herrera A, Schlievert PM. Staphylococcal superantigens interact with 
multiple host receptors to cause serious diseases. Immunol Res. 2014 Aug;59(1-3):177-
81. 
52. Stebbings R, Eastwood D, Poole S, Thorpe R. After TGN1412: recent developments 
in cytokine release assays. J Immunotoxicol. 2013 Jan-Mar;10(1):75-82. 
53. Williams SA, Greene WC. Regulation of HIV-1 latency by T-cell activation. Cytokine. 
2007 Jul;39(1):63-74. 
54. Chow CW, Rincon M, Davis RJ. Requirement for transcription factor NFAT in 
interleukin-2 expression. Mol Cell Biol. 1999 Mar;19(3):2300-7. 
55. Chan JK, Bhattacharyya D, Lassen KG, Ruelas D, Greene WC. Calcium/calcineurin 
synergizes with prostratin to promote NF-kappaB dependent activation of latent HIV. 
PLoS One. 2013 Oct 30;8(10):e77749. 
56. Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses 
by mTOR. Annu Rev Immunol. 2012;30:39-68. 
57. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR 
inhibition. Nat Rev Immunol. 2009 May;9(5):324-37. 
58. Stock PG, Barin B, Hatano H, Rogers RL, Roland ME, Lee TH, et al. Reduction of 
HIV persistence following transplantation in HIV-infected kidney transplant recipients. 
Am J Transplant. 2014 May;14(5):1136-41. 
59. Krakauer T, Buckley M, Issaq HJ, Fox SD. Rapamycin protects mice from 
staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro 
and in vivo. Antimicrob Agents Chemother. 2010 Mar;54(3):1125-31. 
60. Jones RB, O'Connor R, Mueller S, Foley M, Szeto GL, Karel D, et al. Histone 
deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-
lymphocytes. PLoS Pathog. 2014 Aug 14;10(8):e1004287. 
61. Grybko MJ, Bartnik JP, Wurth GA, Pores-Fernando AT, Zweifach A. Calcineurin 
activation is only one calcium-dependent step in cytotoxic T lymphocyte granule 
exocytosis. J Biol Chem. 2007 Jun 22;282(25):18009-17. 
62. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al. 
mTOR regulates memory CD8 T-cell differentiation. Nature. 2009 Jul 2;460(7251):108-
12. 
	 75	 	
63. Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, et al. Ex vivo 
analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest. 
2015 May;125(5):1901-12. 
64. Bosco MC, Rottschafer S, Taylor LS, Ortaldo JR, Longo DL, Espinoza-Delgado I. 
The antineoplastic agent bryostatin-1 induces proinflammatory cytokine production in 
human monocytes: synergy with interleukin-2 and modulation of interleukin-2Rgamma 
chain expression. Blood. 1997 May 1;89(9):3402-11. 
65. Donia M, McCubrey JA, Bendtzen K, Nicoletti F. Potential use of rapamycin in HIV 
infection. Br J Clin Pharmacol. 2010 Dec;70(6):784-93. 
66. Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV 
persistence: implications for curative approaches to HIV infection. Immunol Rev. 2013 
Jul;254(1):326-42. 
67. Jiang S, Herrera O, Lechler RI. New spectrum of allorecognition pathways: 
implications for graft rejection and transplantation tolerance. Curr Opin Immunol. 2004 
Oct;16(5):550-7. 
68. Bruner KM, Murray AJ, Pollack RA, Soliman MG, Laskey SB, Capoferri AA, et al. 
Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat Med. 2016 
Sep;22(9):1043-9. 
69. Pollack RA, Jones RB, Pertea M, Bruner KM, Martin AR, Thomas AS, et al. 
Expression of defective HIV-1 proviruses impairs reservoir measurement and 
elimination. [in press]. 
70. Procopio FA, Fromentin R, Kulpa DA, Brehm JH, Bebin AG, Strain MC, et al. A 
Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected 
Individuals. EBioMedicine. 2015 Jun 27;2(8):874-83. 
71. Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Kosakovsky Pond SL, 
et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature. 
2016 Feb 4;530(7588):51-6. 
72. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification 
of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997 May 
8;387(6629):183-8. 
73. Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms 
and clinical applications. Immunol Cell Biol. 2012 Jan;90(1):85-94. 
74. Matalon S, Rasmussen TA, Dinarello CA. Histone deacetylase inhibitors for purging 
HIV-1 from the latent reservoir. Mol Med. 2011 May-Jun;17(5-6):466-72. 
	 76	 	
75. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, et al. 
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on 
suppressive antiretroviral therapy. PLoS Pathog. 2014 Nov 13;10(10):e1004473. 
76. Abbas T, Dutta A. P21 in Cancer: Intricate Networks and Multiple Activities. Nat Rev 
Cancer. 2009 Jun;9(6):400-14. 
77. Chowdhury IH, Wang XF, Landau NR, Robb ML, Polonis VR, Birx DL, et al. HIV-1 
Vpr activates cell cycle inhibitor p21/Waf1/Cip1: a potential mechanism of G2/M cell 
cycle arrest. Virology. 2003 Jan 20;305(2):371-7. 
78. Kim M, Hosmane NN, Bullen CK, Capoferri A, Yang HC, Siliciano JD, et al. A 
primary CD4(+) T cell model of HIV-1 latency established after activation through the T 
cell receptor and subsequent return to quiescence. Nat Protoc. 2014 Dec;9(12):2755-70. 
79. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after 
acute infection of T cells in vitro. EMBO J. 2003 Apr 15;22(8):1868-77. 
80. Wu L, Grigoryan AV, Li Y, Hao B, Pagano M, Cardozo TJ. Specific small molecule 
inhibitors of Skp2-mediated p27 degradation. Chem Biol. 2012 Dec 21;19(12):1515-24. 
81. Pan XY, Zhao W, Zeng XY, Lin J, Li MM, Shen XT, et al. Heat Shock Factor 1 




Alyssa R. Martin 
(513) 218-6083        1632 Shakespeare St 
amarti81@jhmi.edu       Baltimore, MD 21231 
EDUCATION 
 
The Johns Hopkins University School of Medicine   Baltimore, MD 
August 2012 – February 2017 
PhD, Pharmacology and Molecular Sciences     
 
Emory University         Atlanta, GA 
August 2009 – May 2012 
Bachelor of Science, Biology; Bachelor of Arts, Psychology 
GPA 3.55  
 
Cornell University         Ithaca, NY 




Laboratory of Dr. Robert Siliciano, Department of Medicine, Johns Hopkins University 
School of Medicine 
May 2013 – present  
• Demonstration of a novel use for rapamycin as an immune modulator during 
reactivation of latent HIV-1 expression by ex vivo treatment of primary cells 
• Development of a novel limiting dilution qPCR based assay to measure the size of 
the latent HIV-1 reservoir in infected patients, including optimization and validation 
• Characterization of a primary-cell model for HIV-1 latency; including screening of 
potential pharmacologic latency reversing agents, modulation of transcription factors 
to optimize effective HIV-1 induction, and identification of a novel HIV latency 
reversal mechanism 
• Management of multiple inter- and intra-institution research collaborations 
Centers for Disease Control and Prevention, Division of Viral Hepatitis, Atlanta, GA 
June 2011 – May 2012 
• Development of a novel qPCR assay for hepatitis D virus; including sequence 
analysis, primer design, assay optimization, testing and analysis of clinical samples 
Laboratory of Dr. Steven L’Hernault, Biology Department, Emory University 
September 2010 – May 2012 
• Genetics and development of C. elegans, including performing genetic crosses of 




Sarah Jang, undergraduate student, Johns Hopkins University  01/2014-present 
• Role: Primary advisor during undergraduate research 
Abena Kwaa, PhD student, Johns Hopkins School of Medicine  08/2015-12/2015 
• Role: Primary advisor during laboratory rotation 





Molecular Biology & Biochemistry 
• DNA and RNA isolation, qRT-PCR, western blotting, gel electrophoresis, gel 
extraction and DNA sequencing, molecular cloning, luciferase-based assays, 
CRISPR genome editing 
Cell Biology 
• Primary-cell and cell-line culture and maintenance, magnetic based cellular 
isolations, eukaryotic transfection including lipofection and electroporation 
Immunology & Virology 
• Multicolor flow-cytometry, cell sorting, ELISA, IHC, viral genome editing, viral 
transductions, virus concentration and purification, multiplex cytokine assays, BSL-
2/3 virus handling and safety 
Organismal Biology 




Martin AR, Pollack RA, Capoferri A, Ambinder RF, Durand CM, Siliciano RF. Rapamycin-
mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated 
toxicity. The Journal of Clinical Investigation, Feb 2017. 
 
Besnard E*, Hakre S*, Kampmann M*, Lim HW, Hosmane NN, Martin A, Lin H, Bassik MC, 
Verschueren E, Chan J, Svensson JP, Gramatica A, Conrad RJ, Ott M, Greene WC, 
Krogan NJ, Siliciano RF, Weissman JS, Verdin E. The mTOR complex controls HIV latency. 
Cell Host and Microbe, Dec 2016. 
 
Martin AR and Siliciano RF. Progress toward HIV eradication: case reports, current efforts, 
and the challenges associated with cure. Annual Reviews of Medicine, Jan 2016. [Review] 
 
Laird GM*, Bullen CK*, Rosenbloom DI, Martin AR, Hill AL, Durand CM, Siliciano JD, 
Siliciano RF. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. 
The Journal of Clinical Investigation, May 2015. 
 
Kodani M, Martin A, Mixson-Hayden T, Drobeniuc J, Gish RR, Kamili S. One-step real-time 
PCR assay for detection and quantitation of hepatitis D virus RNA. Journal of Virological 
Methods, Nov 2013. 
 
Under review: 
Pollack RA, Jones RB, Pertea M, Bruner KM, Martin AR, Thomas AS, Capoferri AA, Huang 
S, Karandish S, Hao H, Halper-Stromberg E, Yong P, Kovacs C, Benko E, Siliciano RF, Ho 








PRESENTATIONS & AWARDS 
 
Martin AR, Redd AD, Laird GM, Siliciano RF, Brown D, Ostrander D, Quinn T, Segev D, 
Tobian A, Durand CM. Inducible HIV-1 latent reservoir increases after HIV+ or HIV- solid 
organ transplant. Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, 
WA, February 2017.  
• Young Investigator Scholarship 
 
Martin AR, Pollack RA, Capoferri A, Siliciano RF. Immune modulation with rapamycin 
downregulates toxic effects of T cell activation without impairing HIV-1 latency reversal and 
CTL response. Keystone Symposia Conference on HIV Persistence: Pathogenesis and 
Eradication, Olympic Valley, CA, March 2016. 
• Keystone Symposia Travel Scholarship 
 
Martin AR & Siliciano RF. Immune Modulation with Rapamycin as a Potential Strategy for 
HIV-1 Eradication. Conference on Retroviruses and Opportunistic Infections (CROI), 
Seattle, WA, February 2015. 
 
Martin A, Mixson-Hayden T, Kodani M, Drobeniuc J, Kamili S. Development of a Real-time 
Polymerase Chain Reaction Assay for Detection and Genotyping of Hepatitis D Virus in 
Clinical Samples. Undergraduate Research Presentations at Emory University, Atlanta, GA, 
May 2012. 
• Excellence in Undergraduate Research Award 
 
